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1 Introduction 
1.1 Actin 
Actin has been discovered together with myosin in muscles as a filamentous structure 
in 1942 [1, 2]. Actin was found to be present in most eukaryotic cells and is highly 
conserved [3]. Actin filaments play key roles in cell adhesion[4], endocytosis[5], 
intracellular trafficking [6], maintenance of cell shape[4], polarity[7, 8] and cell 
motility [9, 10]. Filament building proteins with a high structural homology to actin 
were recently found to be present in prokaryotic systems [11].  
Actin exists in a filamentous form (F-actin) and in a globular form (G-actin). F-actin is 
a polar polymer of G-actin with a pointed (-) and a barbed (+) end (Figure 1). One 
filament is composed of two proto-filaments which form a right-handed double helix. 
The actin monomers in each proto-filament are assembled in a head-to-tail manner. 
G-actin is an ATPase and can exist in four different forms: nucleotide-free, ATP-
bound, ADP-Pi bound and ADP-bound. Typically ATP-actin is incorporated into actin 
filaments because the critical ATP-actin concentration is much lower than the critical 
ADP-actin concentration (depending on experimental conditions) [12]. Nucleotide-free 
actin (NFA) has an even lower critical concentration [13]. However, the NFA 
concentration is normally below this critical concentration; moreover, NFA filaments 
are not stable without stabilizing agents. 
 
Figure 1: Structure of the actin filament and actin polymerization. Top: Actin is a polar 
polymer composed of two actin proto-filaments. These filaments form a right-handed double 
helix (long-pitch helices). The actin subunits in the proto-filaments are linked in a head-to-tail 
manner. Bottom: The nucleation phase until the formation of actin tetramers is energetically 
unfavourable, while the elongation phase takes place spontaneously above a certain critical 
concentration. At steady state, monomers are added at the barbed (+) and removed at the 
pointed (-) end. This so called “tread milling” process leads to a stable filament length. 
Filament aging leads to transformation of ATP-actin subunits to ADP-actin subunits. From [14]. 
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Actin polymerization kinetics follows a curve with a sigmoid-like shape (Figure 30), 
which suggests a cooperative actin polymerization mechanism [15]. Actin 
polymerization can be divided into two phases: nucleation and elongation (Figure 1) 
[16]. The nucleation kinetics is very complex [17], while the elongation phase can be 
described by an exponential kinetic model [18]. 
Nucleation includes the formation of actin dimers and trimers and is an energetically 
unfavourable process; the dimer formation is preceded by a lag phase. Starting with 
the formation of a tetramer, elongation is energetically favourable and occurs 
spontaneously at actin concentrations above a certain critical concentration. After 
reduction of G-actin due to filament growth, an equilibrium state is reached. 
At typical physiological pH values, G-actin with its isoelectric point of 5.2 – 5.4 
(α-skeletal muscle actin) [19, 20] is negatively charged. At pH = 7.4 it bears four 
negative charges. Therefore large parts of the surface are negatively charged; local 
extent of the charge depends on the specific amino acids present at the protein 
surface. Nucleation and elongation can be triggered by K+, Mg2+ or Ca2+ which are 
known to partially neutralize this surface charge [21-23]. Upon addition of salt, actin 
undergoes a conformational transition which enables G- to F-actin transition; a 
structural description of this conformational transition was proposed only recently 
[24]. Ca2+ and Mg2+ are thought to bind to several high- and moderate-affinity divalent 
cation binding sites [25]. Mg2+ is known to strongly promote actin nucleation, while 
Ca2+ has been linked to nucleotide exchange. Low-affinity binding sites (also for 
monovalent cations like K+) are important for elongation. Critical concentrations of 
Ca2+ and Mg2+ for induction of actin polymerization are roughly 100 times lower than 
the critical K+ concentration [22]. If the Ca2+ ions associated with G-actin in a solution 
with low Ca2+ concentration are replaced by Mg2+ ions, actin polymerization by K+ is 
greatly accelerated [21]. Critical K+, Mg2+ and Ca2+ concentrations, which are needed 
for the existence of F-actin at equilibrium, have also been described [26]. 
G-actin can associate with and dissociate from both the barbed (+) and the pointed 
(-) ends of actin filaments. Dissociation constants have been measured by electron 
microscopy [27]. At typical actin concentrations between 0.1 µM (75 mM KCl, 1-5 mM 
MgCl2) [28] and 5 µM (50 mM KCl, 1 mM MgCl2), ATP-actin associates with F-actin, 
while ADP-actin dissociates from it [12]. ATP-actin associates faster to the pointed (+) 
than to the barbed (-) end. After ATP-actin association to the barbed (+) end, ATP-
actin undergoes a filament aging process: ATP-actin is hydrolyzed and Pi is released, 
resulting in the ADP-actin form of older filament subunits. At typical G-actin 
concentrations the dissociation of this ADP-actin at the pointed (-) end is faster than 
its association. This process can therefore be described as a treadmilling process, in 
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which the filament grows at the barbed (+) end and shrinks at the pointed (-) end, 
leading to apparent movement of the filament towards its barbed (+) end. Actin 
association is a second order reaction depending on G-actin concentration while 
dissociation is rate limited. Therefore an equilibrium state with stable filament length 
is reached after the elongation phase due to decreased G-actin concentration. 
1.2 Actin-binding proteins, nucleators and elongators 
Actin dynamics in vivo is regulated by many actin binding proteins (ABPs). They can 
bind G-actin (for example profilin, cofilin, Srv2/CAP, thymosin, see below) or/and F-
actin. Capping proteins are an important group of proteins binding to F-actin. They 
block the actin filament from both polymerizing and depolymerising by binding either 
to the barbed (+) end (CapZ) or the pointed (-) end (tropomodulin). ABPs of the 
Gelsolin family can sever actin filaments and subsequently bind to the barbed (+) end. 
ABPs can organize actin filaments by bundling (actinin) or crosslinking them (filament, 
fimbrin). They are also involved in complex tasks of f-actin organization and 
stabilization, as for example in muscle function (tropomyosin, myosin II). It is also 
possible to group many ABPs by conserved structural domains or common actin binding 
sites [29]. It is noteworthy that profilin and thymosin β4, which will be discussed 
below, bind to different actin sites; therefore, a profilin:actin:thymosin β4 complex 
may form under certain conditions [30]. 
Cofilin, a member of the ADF/cofilin family, is a side-binding ABP which destabilizes f-
actin. It inserts between two ADP-actin subunits of one side of a filament, leading to a 
twist on the filament and instability of the filament lattice [31]. Cofilin therefore 
promotes depolymerization at the pointed (-) end and keeps ADP-actin out of the 
cycling actin pool being available for polymerization (Figure 2). ADP-actin can 
dissociate easier from cofilin upon cofilin phosphorylation. 
Profilin is ubiquitous and thymosin β4 is present in most eukaryotic cells. Thymosin β4 
slows actin addition at both the barbed (+) and the pointed (-) end, while the function 
of profilin is more complex to describe: polymerization at the barbed (+) end can be 
either promoted or slowed. Several functions of these ABPs have to be considered: 
(1) Both thymosin β4 and profilin have, together with cofilin, an effect on actin 
turnover (Figure 2). Thymosin β4 inhibits the exchange of ADP for ATP in G-actin. 
Profilin, in contrast, accelerates this actin turnover and thus promotes actin assembly. 
Profilin recruits ATP-actin by binding to a complex of Srv2/CAP-ATP-actin and by 
subsequent release of exchange factor Srv2/CAP [32]. This exchange factor Srv2/CAP 
has a higher affinity to ADP-actin and binds to ADP-actin before nucleotide exchange. 
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Figure 2: Roles of profilin, cofilin and Srv2 in actin turnover. From [32]. 
 
(2) The interaction between the ATP-actin-profilin complex and actin monomers or 
the barbed (+) end is sterically hindered; the polymerization rate of profilin-ATP-actin 
is therefore slower than the rate of profilin-free ATP-actin. (3) Both profilin and 
thymosin β4 are ATP-actin monomer sequestering proteins and thus reduce the total 
actin pool available for polymerization of profilin-free ATP-actin. This explains the 
high ratio of G-actin : F-actin in vivo. PIP and PIP2 can stimulate the dissociation of 
profilin from actin; thus profilin can be considered a transmitter of cell membrane 
signals to the actin cytoskeleton. (4) However, an ATP-actin-profilin complex can 
speed up elongation at the barbed (+) end dramatically in the presence of formin: the 
FH1 domain of formin proteins being bound to the barbed (+) ends of f-actin can 
recruit this complex (more about formins below).  
 
Actin nucleators (Figure 3) promote actin nucleation by reducing the energy barrier 
for the formation of actin dimers or trimers (chapter 1.1). They can either stabilize 
actin dimers / trimers, or they can mimic an actin tri- / tetramer and thus enable 
directly the energetically favourable elongation process. There exist three nucleator 
classes [33]: 
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Figure 3: Classification of nucleation factors. Class 1 nucleation factors need nucleation 
promoting factors (NPF)s like N-WASP for proper function. From [33]. 
 
Class 1: Arp2/3. These proteins nucleate actin as new side branches from pre-existing 
f-actin. They work together with Nuclear Proliferation Factors (NPFs), which induce 
conformational changes in Arp2/3 and recruit actin monomers. NPFs are WASP, 
NWASP, WAVE (also known as SCAR), WASH, WHAMM, JMY, Cortactin and HS1. After 
nucleation, Arp2/3 remains at the pointed (-) end, but is later released from aged 
filaments. Cofilin catalyzes this Arp2/3 and branch dissociation [31]. 
Class 2: Formins are known to promote actin nucleation with their dimerized FH2 
domain. The FH2 dimer promotes actin nucleation[34, 35] probably by bridging two 
linear actin monomers, leading to the formation of unbranched actin filaments [34, 
36]. The formin dimer remains associated with the barbed (+) end of the nucleated 
filament. 
Class 3. WH2 containing proteins [33]. The WASP-homology 2 domain (WH2) domain 
binds G-actin. In Class 3 nucleators, at least two WH2 domains are linked. Together 
with recruited actin monomers, they mimic an f-actin nucleus and therefore promote 
actin polymerization from this nucleus. Examples for Class 3 nucleators are Spire, Cobl 
and Lmod. 
 
The variety of nucleators offers the tools for a differential regulation of actin 
dynamics in several contexts of cellular function (Figure 4). 
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Figure 4: Function and localization of f-actin and its nucleators  in mammalian cells. 
ARP2/3 promotes filament branching and requires nucleation promoting factors (NPF)s like 
WASH and WAVE. mDia1, mDia2, mDia3, FRL1, FMN1, FHOD1, INF1, INF2, DAAM1 and DAAM2 
are formins (see chapter 1.2.1). From [37]. 
 
Formins also can serve as elongators; they remain associated with the barbed (+) end 
during elongation. Details will be discussed in the following subchapter. Other actin 
elongation factors are Ena/VASP proteins; they recruit profilin-actin, similar to the 
formin FH1 domain [33]. Clustered VASP proteins form tetramers and can greatly 
accelerate elongation [38]. They exhibit only negligible nucleation activity at 
physiological salt concentrations [39]. 
  
Figure 5: Classification of elongation factors. Formins can also serve as nucleators (Class 2, 
see Figure 3). From [33]. 
  
 - 13 - 
1.2.1 Structure and function of formins 
The term “formins” was introduced in 1990 for a group of proteins that typically 
contain > 1000 amino acids encoded by different transcripts of the murine limb 
deformity (LD) gene [40]. The FH2 (formin homology 2) domain, usually 400-500 amino 
acids long, defines the formin family and is used for phylogenetical classification [41, 
42]. Formins can be grouped into yeast formins (budding and fission yeast), plant 
formins, non-yeast fungi formins and metazoans. Currently the following metazoan 
formin classes are described: Diaphanous (DIA), Dishevelled-associated activators of 
morphogenesis (DAAMs), formin-related proteins in leukocytes (FRLs), formin 
homology domain proteins (FHODs), formins (FMNs), inverted formins (INFs) and 
Delphilin. About 15 different formins have been identified in mammals [37, 43]. 
Budding yeast expresses two formins, Bni1p and Bnr1p [44]. X-ray structures of FH2 
domains of yeast Bni1p [45], human Daam1 [46] and mDia1 [47] show that the atomic 
FH2 structure is highly conserved. Therefore it is not surprising that the FH2 domain is 
the molecular centre of formin function. It has been shown that the FH2 domain of 
Bni1p alone can catalyze actin polymerization in vitro [48]. However, even though the 
atomic FH2 structures of homologous formin proteins are similar, their effect on actin 
polymerization varies greatly [43]. It is an open question which (minor) structural 
features are responsible for these (probably kinetic) differences. 
The FH1 (formin homology 1) domain is less conserved than the FH2 domain [49]. 
However, the only known formin without a FH1 domain is ForC in Dictyostelium 
discoideum [50].  
 
A diaphanous inhibitory domain (DID) and a diaphanous auto-regulatory domain (DAD) 
are part of mammalian mDia1 and mDia2 formins (Figure 6). Similar domains can also 
be found in other formins like FRLs and DAAMs. The DID domain can interact with the 
DAD domain and thus block formin activity. Rho family GTPases like mammalian RhoA 
can bind to the formin (to the GBD) and prevent the DID from interacting with DAD, 
leading to the activation of formin [51]. In yeast, several GTPases including Rho1p, 
Rho3p, Rho4p and Cdc42p have turned out to play key regulatory roles in the 
spatiotemporal regulation of the actin cytoskeleton [52-54]. A dimerization domain 
(DD) C-terminal to the DID domain can dimerize; it is involved in autoinhibition in 
mDia1 [55]. 
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Figure 6: Domains of mammalian mDia1. Domain name abbreviations: G: GTPase binding 
region for RhoA binding; DID: Diaphanous Inhibitory; DAD: Diaphanous autoinhibitory domain; 
DD: dimerization domain; CC: coiled coil; FH1 – FH3: formin homology 1 – 3; GBD: GTPase 
binding domain. GBD and FH3 are structural domains. FH3 is not established. From [56]. 
 
The FH2 domain of yeast formin Bni1p is structurally and functionally well 
characterized (Figure 7). It is a therefore a good model protein; in the following part 
of this subchapter, structure-function relationships of formin domains will be 
discussed in detail, with a focus on the FH2 and FH1 domains of yeast formin Bni1p. 
The dimerization of its FH2 domain is highly stable: analytical ultracentrifugation 
shows that the FH2 dimer is very stable even at c(NaCl)=200 mM [57]. An 
electrophoretic mobility assay confirmed the stability of the FH2 dimer [45]. The 
dimerization takes place in a head-to-tail manner: The “post” subdomain of one FH2 
domain interacts with the “lasso” subdomain of the other FH2 domain (Figure 7). The 
dimer is often described as a donut-shaped ring. It was reported that truncated yeast 
formins (Bni1p, FH2 and FH1-FH2 constructs) can form tetramers in solution (SLS 
analysis) [58]. FH1-FH2 constructs of mDia1 were also found to oligomerize [59]. 
 
 
Figure 7: Structure of the dimerized Bni1p FH2 domain. One of the FH2 monomers is printed 
in colour. The N-terminal lasso subdomain of one FH2 monomer is in contact with the C-
terminal lasso subdomain of the other FH2 monomer: The dimerization takes place in head-to-
tail manner. From [45]. 
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Formins also function as elongators. The FH1 domain recruits profilin-actin and is the 
main elongation factor because it promotes elongation greatly. The role of the FH2 
domain is ambiguous. On one hand, the FH2 domain competes with capping proteins 
for filament barbed (+) ends and can thereby facilitate elongation. On the other hand, 
FH2 domains can themselves limit the accessibility of the barbed (+) ends and thereby 
inhibit elongation to a variable extent [51]. During elongation, the FH2 domain is 
responsible for keeping the FH1 domains close to the barbed (+) end. This constant 
barbed end association is made possible by a processive mechanism [60, 61]: There 
are two different hypotheses as to how FH2 can stay at the barbed (+) end during 
filament elongation [62]. In the both hypotheses, the FH2 domain can adapt an 
“open” or a “closed” conformation. A flexible linker subdomain between the N-
terminal “lasso” subdomain and the “knob” subdomain allows the FH2 dimer to adapt 
these conformations (Figure 8). The “stair-stepping” hypothesis explains processive 
formin association with only two alternating states. During the closed state, the FH2 
dimer is bound to three terminal actin subunits with both its knob and post sites. The 
trailing FH2 subunit “steps” to the end of the filament, so that its post binding site 
becomes exposed (“open state”); the FH2 dimer is then bound only to two actin 
subunits. By addition of an actin monomer, the FH2 changes to the “closed” state 
again. In this “stair-stepping” hypothesis, the FH2 domain “steps” off the actin 
filament prior to actin addition. In the other hypothesis, called “step second” 
hypothesis, the FH2 domain steps forward only after the actin monomer addition. The 
FH2 dimer is thought to be in a rapid equilibrium between two states with an 
energetically favourable closed confirmation or an energetically unfavourable open 
confirmation. In contrast to the other model, this open state is accessible already 
prior to the movement of the FH2 domain.  Addition of an actin monomer to such an 
unfavourable open state leads to a third state in which the favourable closed FH2 
confirmation is inaccessible; that promotes the stepping of the FH2 dimer to the end 
of the filament so that the closed confirmation is accessible again. 
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Figure 8: Structure of the FH2-actin complex and flexibility of the FH2 dimer. Three actins 
are bound to two FH2 monomers (coloured cylinders). The flexibility of the linker between the 
lasso and knob region is illustrated. From [36]. 
 
The FH1 domain promotes elongation by the addition of profilin-actin to the growing 
barbed end [35]. Recent kinetic model for FH1FH2 mediated actin elongation might 
explain how excessive free profilin can slow elongation: profilin can remove actin 
subunits from the barbed (+) end and thus slow elongation [63]. Figure 9 shows two 
alternative elongation mechanisms: one FH1-dependent by addition of profilin-actin, 
and one FH1-independent by “classical” direct addition of ATP-actin or profilin-actin 
to the growing barbed (+) end. 
 
Figure 9: FH1-dependent and independent actin subunit addition pathways. FH1-dependent 
pathway: 1-2’-3’-2-3. FH1-independent pathway: 1-2-3. F-actin substrands are coloured in light 
blue and grey. Actin monomer: grey. Profilin: dark blue. FH2 domain: violet. Proline-rich 
profilin binding sites of the FH1 domains: yellow. The FH1-independent elongation pathway can 
also take place in the absence of profilin. From [62]. 
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The FH1 domain has several polyproline tracks which can bind SH3 domains of profilin. 
FH1 domain structure and activity varies between species. It has been shown that the 
number of polyproline tracks in an FH1 domain is correlated with elongation rates 
[48]. This number can range from one (Fus1p in Schizosaccharomyces pombe) to 14 
(mDia1 in Mus musculus) [62]. It can vary within a single cell type; Dictyostelium 
discoideum has 10 formins with 1 – 8 polyproline tracks in their FH1 domains [49]. 
The number of prolines within one track usually also varies within and between 
species. For example, the four Bni1p polyproline tracks contain between 5 and 13 
prolines [48]. The kD between profilin and a polyproline depends highly on its length 
[64]. However, the mechanistic impact of the different polyproline track lengths 
within one FH1 domain is still not understood.  
The FH1-dependent addition of profilin-actin to the barbed end can be governed by 
the FH1 domain in two kinetically distinguishable ways: On the one hand, repeated 
profilin-actin recruitment and release by polyproline domains could increase the local 
profilin-actin concentration at the barbed (+) end (diffusion limited kinetics). On the 
other hand, the polyproline domain could effectively deliver the profilin-actin 
complex to the barbed (+) end; a ring complex is formed (concentration limited 
kinetics) [62]. The formation of a ring complex requires flexible linkers between the 
FH2 domain and the polyproline track delivering the profilin-actin complex. It is not 
clear, how much each of these mechanisms contributes to formin function, and how 
sensitive formin function is to structural variations impeding or promoting these 
mechanisms. 
1.3 Electrostatics and electrolyte conditions  
1.3.1 Electrolyte conditions in human and yeast 
Before discussing the impact of electrostatics and electrolyte conditions on actin 
polymerization, a short overview of in vivo electrolyte conditions in human and yeast 
will be given in this subchapter. 
The homeostasis of intra- and extracellular salt concentrations is a central aspect in 
human physiology [65]. Potassium is the predominant cation in the cell, its 
intracellular concentration is 155 mmol/l, the extracellular concentration is 4 mmol/l. 
Strong derivations from this value are dangerous [66]. Sodium concentration 
distribution is virtually inverse: the intracellular concentration is 12 mmol/l and the 
extracellular concentration is about 145 mmol/l. Proteins have the by far biggest 
contribution to intracellular negative charge, while chloride is the predominant anion 
in extracellular space (120 mmol/l). 
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The electrolyte conditions in Saccharomyces cerevisiae are different because yeast is 
very adaptive to many conditions; variable electrolyte concentrations can be found 
inside the cell depending on the concentrations outside [67]. Reported intracellular 
concentrations depend on the strain [68, 69] and on experimental conditions. The 
intracellular pH value in yeast cells is usually around 6 [70]; therefore cationic 
ammonium is abundantly present. The most abundant intracellular metallic cation is 
potassium. Its intracellular concentration range was reported to be 8 – 56 mmol/100 g 
[67]. Therefore it is not surprising that yeast cells tolerate media with KCl 
concentrations from 2 µM to 2 M [71]. Unfortunately, intracellular salt concentrations 
using the unit mol/l are rarely reported; the intracellular potassium concentration 
range that can be found in literature is 200-330mM [71, 72]. However, in a 1 M NaCl 
solution, intracellular potassium can drop to 92 mM, while sodium concentration rises 
from negligible concentrations to 283 mM [72]. Intracellular anionic concentrations 
can vary remarkably. A chloride concentration range reported in one publication was 
11-140 mmol/100g; in the same publication, the phosphate range was mentioned to 
be 40-65 mmol/100g; other quantitatively important ions were sulphate and 
magnesium [67]. 
1.3.2 Effect of electrostatics and electrolyte conditions on actin 
polymerization without and with formin 
Dissociation and rate constants are essential for modelling the kinetics of the actin 
polymerization process [63]. The determination of rate constants and dissociation 
constants was useful for evaluation of specific interactions, which have been discussed 
to take place during actin nucleation (study in the absence of formin) [17]. 
Kinetics and thermodynamics of molecular interactions are related by the equation 
[1] ( )ln lnb D kG RT K RT k
−
+
 
∆ = =  
 
 
∆Gb is the binding free energy. A major part of the binding free energy is the 
electrostatic binding free energy. For example, the interaction of two oppositely 
charged protein surfaces is often favourable because of a negative electrostatic 
binding free energy. The electrostatic binding free energy of a protein complex 
depends on the interactions of the protein complex and on the electrostatic part of 
the solvation energy: A reduced total protein surface implies less interaction between 
the solvent and the proteins. Therefore the interaction of oppositely charged protein 
surfaces is not necessarily favourable in terms of the electrostatic binding free 
energy. 
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The salt concentration can have an impact on electrostatics; salt can cover protein 
surfaces and effectively reduce their charge. It can change the electrostatic part of 
the solvation energy likewise. In order to understand the impact of electrostatics on 
actin polymerization it is therefore necessary to investigate the impact of electrolytes 
on actin polymerization. 
The electrolyte conditions in S. cerevisiae can vary remarkably, as mentioned in the 
previous subchapter. An impact of salt on actin polymerization in vitro would 
therefore almost certainly have consequences in vivo. Electrostatics of actin 
polymerization in the absence of formin has been studied extensively: electrostatics 
plays an important role in the actin nucleation mechanism (without formin) [17]. 
However, a salt effect in terms of a change of nucleation kinetics has been observed 
only for very low or very high KCl concentrations. The KCl-triggered actin 
polymerization speed in the absence of formin is constant at 20 mM < c(KCl) < 
150 mM, provided that Mg2+ ions are present [21, 22, 73]. Below the critical 
concentration c(KCl) = 10 mM, there is practically no actin polymerization observable 
[26]. Instead, aggregates of ATP-actin appear at c(KCl) = 7.5 mM; they are different 
from the nuclei needed for the formation of F-actin [74]. Above 150 mM, the actin 
polymerization becomes slower with increasing KCl concentration. There is a 
pronounced pH effect on actin polymerization in the absence of formin: a lower pH 
accelerates actin polymerization [21, 25]. The pH effect was explained (for 6 < pH < 8 
only) with the stabilization of dimers and with the induction of the salt-induced 
conformation by protons [25]. In this context, it could be worth considering the 
recently published structural description of the conformational transition from G- to 
F-actin [24]. An effect of temperature on actin polymerization has also been reported 
[75].  
The effect of electrostatics on formin and FH2 function has not been investigated yet. 
A salt effect on formin mediated actin polymerization would imply that electrostatic 
forces are mechanistically important for formin function in actin polymerization. 
Experiments taking advantage of a salt effect could furthermore be used for the 
validation of thermodynamic and kinetic models of specific formin-mediated actin 
polymerization steps. 
Experiments addressing the presence or absence of a salt effect on FH2 mediated 
actin polymerization will be performed in this work. Moreover, electrostatic energies 
will be calculated by the Poisson Boltzmann equation. Such calculations could support 
the (non)impact of electrostatics and salt concentration on FH2 function. 
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1.3.3 Other possible implications of a salt effect  
Apart from the impact of electrolyte conditions on formin mediated actin 
polymerization via electrostatics, there would be other important implications arising 
from a salt effect on formin mediated actin polymerization. 
- A salt effect could partially explain structural and functional differences of formin 
proteins - in particular of the FH2 domain - between organisms. 
- A regulator like salt is often more readily available than a protein. The energy spent 
for synthesis of a regulatory protein and the energy needed for protecting its genetic 
material from damage would be saved. Salt would be a reasonable regulator for a 
complex salt regulating system via modulation of formin mediated actin 
polymerization: Regulation of ion uptake and output in yeast involves several channels 
and even transport systems [68, 71, 76, 77]. 
- If salt has an impact on the function of yeast formin, it might also have an impact on 
in vitro research and could help to explain different results yielded from in vitro and 
in vivo experiments [78]. 
- For discovery of specific drug inhibitors of the FH2 domain (chapter 1.5), knowledge 
about the presence or absence of a salt effect is crucial. 
 
1.4 Formins and disease 
In order to evaluate the possible role of formins in human disease, the different 
critical functions of formins in mammalians have recently been reviewed and linked to 
more or less specific disease mechanisms by DeWard et al (specific associations of 
human formins: Table 1) [79]. Defects in cytokinesis can contribute to cancer genesis 
[80]. Formins play a key role in cytokinesis because they organise the contractile actin 
ring during cell division [41] and they stabilize microtubules [81] during cell division. 
Formins probably also play an important role in cancer cell migration and invasion 
[82]: mDia1 is involved in polarization and migration of cancer cells and is regulated 
by Rho GTPases [52, 83]. It also takes part in focal adhesions of migrating cancer cells 
[84]. The involvement of mDia2 in cancerogenous processes is less established, but 
more specific [79]. mDia2 seems to prevent membrane blebbing by control of cortical 
actin assembly [85, 86]. Blebbing is part of the amoeboid migration mode and a 
related microvesicle formation process of prostate and cervical cancer cells. A recent 
study provides evidence that mDia2 is involved in the genesis of murine and human 
metastating prostate cancer based on these mechanisms [87]. 
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Table 1: Specific associations of human formins to disease. Modified from [79]. 
Name Chromosome Disease relevancy
mDia1 / DIAPH1 5q31 5q- Myelodysplastic syndrome
DFNA1 non-syndromic deafness
mDia2 / DIAPH3 13q21.2 Chromosome deletion in metastatic prostate cancer
mDia3 / DIAPH2 Xq21.33 Premature ovarian failure
FMNL1 17q21 Increased expression in lymphoid malignancies and
peripheral blood leukocytes from CLL patients
FMNL2 2q23.3 Increased expression in colorectal cancer
 
From a pathophysiological perspective, cellular migration and adhesion are important 
for other processes than cancer as well. Macrophage migration, cell spreading and 
lamellipodia formation are influenced by the Formin-related gene in leukocytes (FRL) 
protein, another formin [88]. In light of this finding, it is of interest that the 
expression of FMNL-1, a protein of the FRL group, is elevated in blood leukocytes from 
CLL patients and in human lymphoid cancer cell lines [89]. Another formin, mDia1, 
seems to be involved in T cell development, proliferation and emigration [79]. 
Similarly, mDia1 also plays a role in neutrophile migration and activation [90]. Other 
processes in the hematopoietic system in which formins reportedly play a role include 
the enucleation of maturating erythrocytes [91] and actin assembly in activated 
thrombocytes [92]. 
Hematopoietic diseases, in which the involvement of mDia1 is discussed very 
specifically, are the myelodysplastic syndromes (MDS) del(5q). Myelodysplastic 
syndromes are a heterogenic group of bone marrow diseases associated with an 
ineffective haematopoiesis in terms of quantity and quality, peripheral cytopenia, 
cell-rich dysplastic bone marrow, and oftentimes presence of blasts [93]. MDS del(5q) 
are low-risk variations of MDS according to the International Prognostic Scoring System 
(IPSS) [94]. 5q deletions similar to those of MDS del(5q) can also be found in related 
proliferative disorders, including variations of acute myeloic leukaemia (AML), 
myeloproliferative neoplasms (MPN) and overlap syndromes. Lenalidomide, a 
derivative of thalidomide, is effective particularly in MDS del(5q) [95]. MDS del(5q) is 
histopathologically characterized by an increased presence of megakaryocytes. mDia1, 
which is coded by DIAPH1 on chromosome 5q, was found to be less expressed in mice 
with MDS del(5q) [96]. In the same publication, it is reported that ∆mDia1 knockout 
mice showed a marked increase in haematopoietic progenitor cells and other 
symptoms accounting for a role of mDia1 in MDS del (5q). Together with the 
knowledge of Rho GTPase dependent mDia1 activity and some other nearby deletions, 
a comparatively detailed mechanism for pathogenesis of this disease has been 
proposed. The involvement of Rho GTPases is corroborated by the finding that 
additional knockout of RhoB leads to a more severe disease [97]. 
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In order to discuss the role of formins in developmental disorders, it is useful to 
briefly recall their role in key cellular processes. The role of mDia1 and mDia2 has 
been discussed in the context of cancer in the beginning of this subchapter. Another 
formin being an important candidate for human developmental disorders is the 
dishevelled-associated activator of morphogenesis-1 (DAAM1). The formins Fmn1-IV 
and dDia2 are non-human analogues of this protein. The importance of these proteins 
for cellular migration and adhesion has been demonstrated [98, 99]. A defect in Fmn1-
IV, for example, ultimately leads to kidney aplasia in mice [100]. Initially, Fmn 
(formin) genes were discussed as candidates being responsible for an observed limb 
deformity in mice [40]. It turned out later that in fact the Gremlin gene accounted for 
this defect [41]. However, a very rare human syndrome, which was claimed to be 
related to the limb deformity disorder, but might in fact be related to the Fmn1-IV 
defect in mice, is the severe Acro-Renal-Uterine-Mandibular syndrome [101]. 
Few specific human developmental disorders related to formin dysfunction have been 
identified until now. In a population with autosomal dominant non-syndromic deafness 
(DFNA1) a frameshift in the DIAPH1 gene was observed; this leads to the expression of 
a truncated mDia1 protein [102]. Due to the truncation of the C-terminal part of 
mDia1 and possible interruption of the DAD-DID interaction, a gain-of-function 
mechanism can be considered. Premature ovarian failure (POF) may be related to a 
breakpoint in the gene of mDia3 [103]. However, experimental proof for this 
hypothesis is still lacking. Actin skeleton defects in oocytes might, for example, be 
studied with methods allowing the undisturbed observation of actin filaments in vivo 
[104].  
1.5 Drugs targeting interactions between FH2 and actin 
In recent years, the development of inhibitors targeting actin nucleators and 
elongators has made progress [105]. Those inhibitors can, as a first step, find 
application in experimental research. With a growing number of known nucleators and 
elongators, they could help to understand the complex system of actin nucleators and 
elongators, especially under in vivo conditions. However, the development of drugs 
targeting protein-protein interactions is a challenging task [106, 107]. Binding of drugs 
to active centres of enzymes is often stronger than to protein-protein interaction 
sites. Protein-protein interaction sites are often large, with low interaction energies 
(“anchors”) [108]. According to the “rule of five” [109], the size of a drug is limited 
because a high molecular weights reduces its bioavailability. 
The Arp2/3 complex can be inhibited by CK-666 and related compounds [110]. Small 
molecules have been also been developed for the inhibition of formin-mediated actin 
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polymerization (Figure 10). The “Small molecule inhibitor of formin homology 2 
domains” (SMIFH2) inhibits the FH2 domain of diverse formins, namely mDia1, mDia2, 
Bni1p, Fus1, Cdc12p and CYK-1 [111]. The compound has undergone several tests 
including in vivo experiments and is commercially available. It interrupts the 
interaction between actin and the FH2 domain. Interestingly, it could be confirmed 
that the compound probably interacts with the FH2 domain and not with actin. 
However, due to lacking specifity, the compound is far from any medical application 
[112]. In another recent study, two other compounds and their derivatives were found 
to block FH2 activity [113]. Studies were performed in vitro only. One of the two main 
compounds (Beryllon II, Figure 10.b) was found to inhibit mDia1, mDia2 with an IC50 <= 
0.5 µM, and mDia3 with an IC50 of only 3.1 µM. The other compound (Figure 10.c) was 
found to inhibit mDia1 and mDia2 with an IC50 of 2.1-2.2 µM, while mDia3 was not 
inhibited. It also inhibited INF2 and FRL1 with less affinity. 
It is of interest to understand how these drugs bind to FH2 domains, which has a 
known atomic crystal structure. Better functional understanding of these FH2 domains 
and more structural knowledge about their interactions with actin would help to make 
informed speculations about molecular interactions of FH2 domains that have no 
atomic structure available. Those speculations might be possible because the 
secondary and atomic FH2 structures of different FH2 homologues seem to be similar 
[46, 47]. Together with knowledge about the interaction of small molecule inhibitors 
with the FH2 domain, it could be possible to rationally develop inhibitors of specific 
formin isoforms. By the time these inhibitors are developed, several clinical 
applications might be within sight. The concept of multidrug targeting [114] might 
find application to increase drug specifity; for this approach, detailed understanding 
of protein and drug interactions will be required again. For in vitro drug discovery and 
for understanding the binding properties of the FH2 surface, it is important to know 
how salt influences the electrostatic properties and the function of the FH2 domain. 
 
Figure 10: Inhibitors of formin-mediated actin polymerization. All compounds were found to 
inhibit FH2. a. SMIFH2, modified from [111]; b. Beryllon II, modified from [113]; c. another 
inhibitor from the same study. 
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1.6 Aim of this work 
 
The aim of this work is to understand formin structure-function relationships better. 
In vitro experiments should be based on cloned and expressed constructs derived from 
yeast Bni1p (Saccharomyces cerevisiae). 
 
1. The FH1 domain typically contains polyproline tracks. The size and number of 
tracks differ between and within species. The linker length between the tracks is also 
variable. In this work, different constructs containing the structurally well- 
characterized FH2 domain and a tailor-made FH1-like linker and polyproline track 
should be cloned and expressed. Their linker and polyproline track length should be 
varied. If the constructs can be expressed, pyrene and TIRF assays could be used to 
experimentally investigate the influence of polyproline track length and linker length 
on formin function. The constructs should be suited for mathematical modelling so 
that an experimental evaluation of mathematical models of both diffusion and 
concentration limited actin polymerization kinetics is possible. 
 
2. The impact of salt concentration on FH2 function should be addressed in this work. 
A construct containing only the structurally well-characterized Bni1p FH2 domain will 
be cloned and expressed. The expressed protein will be subject to biophysical 
experiments (pyrene assays, epifluorescence microscopy) in order to investigate the 
presence or absence of a salt effect on FH2 function on actin polymerization. A salt 
effect would account for a major role of electrostatics in the interaction between FH2 
and actin. Electrostatic interaction between FH2 and actin will therefore also be 
addressed computationally for different KCl concentrations: Electrostatic binding 
energies will be calculated and the electrostatic surface potential will be visualized. 
The FH2 domain has recently become a target for inhibitors of formin mediated actin 
polymerization. An area of actin-FH2 interaction, which might be sensitive to a salt 
effect, will be identified. Such area might also be sensitive to inhibitors if these 
inhibitors turn out to interfere with the electrostatic protein-protein interaction 
between FH2 and actin. In order to evaluate whether the identified area is a good 
protein-protein inhibitor binding site candidate, solvent accessible surface areas 
(SASA) will also be calculated. 
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2 Results and discussion 
2.1 Formin constructs for structure-function analysis of the FH1 
domain 
2.1.1 Overview 
All constructs to be cloned and expressed contain the functionally important Bni1p 
FH2 domain. Most constructs should also contain one polyproline track or variations 
thereof. The linker between the FH2 domain and the polyproline track should be 
tailor-made. The linker and polyproline track length should be varied. It was intended 
to perform pyrene and TIRF assays with the expressed constructs to analyze the effect 
of these structural variations on formin function. All constructs will be HIS-tagged. 
The cloning / expression constructs (Figure 11) can be grouped into 
(1) Reference and control constructs: These constructs equal to a FH2 domain with or 
without a truncated Bni1p FH1 domain. A construct very similar to the FH2 
construct was reported in literature (1349 – 1766, also HIS-tagged) [48]. The 
crystal structures of similar constructs were reported (1Y64 [36] residues 1327-
1769 in complex with actin, 1UX5 [45] residues 1350-1760). The 1228-FH1FH2 
(Bni1p residues 1228-1769) and the 1312-FH1FH2 construct were both reported in 
literature before and used for functional studies [48]. Construct 1321-FH1FH2 is 
similar to 1312-FH1FH2, but more comparable to other constructs of in this work. 
(2) (P)x-FH2 constructs: These constructs contain one polyproline domain (4 ≤ x ≤ 14), 
connected to the Bni1p FH2 domain. They should be used in order to study the 
impact of polyproline track length on formin function. (P)x -FH2 constructs would 
be good candidates for biomathematical modelling: The interaction of polyproline 
with profilin has been quantitatively described [64]. 
(3) (GS)x-FH2 constructs: These constructs contain one polyproline domain with 6 
prolines, connected to the Bni1p FH2 domain with a (GS)x linker of variable length 
(3 ≤ x ≤ 15). They should be used in order to study the impact of linker length on 
formin function. It is possible to model the (GS)y linker with a wormlike chain 
model [115]. Therefore development of biomathematical models in order to fit the 
results should be possible. 
(4) Other constructs: Lifeact-FH2 and WH2-FH2. Lifeact[116] and WH2 both bind 
actin, therefore the target proteins Lifeact-FH2 and WH2-FH2 might mimic FH1-
FH2, in which FH1 binds profilin-actin (and not actin).  
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Reference and control constructs: 
 
Construct 44  expected amino acid sequence    exp. MW    
success 
FH2    4  4  MQIKSAV(...)       51.42590 kDa   
1321-FH1FH244MPPAPPMMPASQIKSAV(...)     52.40314 kDa 
1312-FH1FH244MLSSTDGVIPPAPPMMPASQIKSAV(...)    53.26309 kDa 
1228-FH1FH2  44 MLSTQSSVLSSQPPPPPPPPPPVPAKLFGESLEKEKKSEDDT 
VKQETTGDSPAPPPPPPPPPPPPMALFGKPKGETPPPPPLPS4 
VLSSSTDGVIPPAPPMMPASQIKSAV(...)    61.89731 kDa 
 
 
(P)x-FH2 constructs 
 
Construct 44  expected amino acid sequence    exp. MW 
(P)4-FH2 4   MPPPPASQIKSAV(...)      51.97255 kDa 
(P)6-FH2   4 MPPPPPPASQIKSAV(...)      52.16679 kDa 
(P)8-FH2    4MPPPPPPPPASQIKSAV(...)     52.36103 kDa 
(P)10-FH2    MPPPPPPPPPPASQIKSAV(...)     52.55527 kDa 
(P)12-FH2    MPPPPPPPPPPPPASQIKSAV(...)     52.74951 kDa 
(P)14-FH2    MPPPPPPPPPPPPPPASQIKSAV(...)     52.94375 kDa 
 
(GS)x-FH2 constructs 
 
Construct  44expected amino acid sequence    exp. MW 
(GS)3-FH2   4MPPPPPPGSGSGSQIKSAV(...)     52.44101 kDa 
(GS)6-FH2   4MPPPPPPGSGSGSGSGSGSQIKSAV(...)    52.87340 kDa 
(GS)9-FH2   4MPPPPPPGSGSGSGSGSGSGSGSGSQIKSAV(...)   53.30579 kDa 
(GS)12-FH2   MPPPPPPGSGSGSGSGSGSGSGSGSGSGSGSQIKSAV(...)  53.73818 kDa 
(GS)15-FH2   MPPPPPPGSGSGSGSGSGSGSGSGSGSGSGSGSGSGSQIKSAV(...) 54.17057 kDa 
 
other constructs 
 
Construct 44  expected amino acid sequence    exp. MW    
Lifeact-FH244MMGVADLIKKFESISKEEASQIKSAV(...)   53.49032 kDa   
WH2-FH2 4  4 MSGNKAALLDQIREGAQLKKVEQNASQIKSAV(...)   54.07697 kDa 
 
 FH2 region:   highlighted yellow  cloning + expression successful 
 Linker region:  highlighted cyan   
 Polyproline track: highlighted green  only cloning successful  
       
        cloning + expression not successful 
 
Figure 11: Cloning and expression of formin constructs in this work. 
 
All constructs but Lifeact-FH2 and WH2-FH2 were cloned successfully (Figure 11). 
However, the FH2 domain is the only protein successfully expressed in this work; it 
was needed for the experiments to investigate a salt effect on FH2 (chapter 2.2). 
Without the expression of the other construct, studies on the effects of FH1 structure 
variations on formin function are not possible. In the next part of this chapter, 
expression results will be discussed further. 
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2.1.2 Cloning and expression of reference and control constructs 
30.8 mg of FH2 protein were successfully expressed using only a part of the available 
biomass for lysis and purification. Final concentration was 2.80 mg/ml at a purity of 
98%. The expected mass in LC-MS was 51424.6 D, the measured mass was 51424.1 D. 
FH2 was subsequently used in pyrene assays confirming the functionality of the 
protein. 
Attempts to express 1321-FH2, 1312-FH2 and 1228-FH2 failed largely. 1312-FH2 (one 
polyproline track) and 1228-FH2 (entire FH1 domain) have been successfully expressed 
in literature [48]. With the same conditions described therein [48, 61, 117] expression 
was not successful in this work.  
The specific E. coli Bl21 Codon Plus DE3 RP strain with a FH2 construct in a PQE-70 
vector, which was successfully used by the core facility to produce FH2 protein, was 
used as a control for own test expressions. This control was positive (Figure 12) in a 
Western Blot (“own test expression” protocol in chapter 4.3) (Figure 12). This FH2 
construct underwent extensive cloning procedures including cloning into another 
substrain (again E. coli Bl21 DE3 CodonPlus RP). The protein expression level was 
extremely low without and with induction, as shown in the Western Blot (Figure 12). 
The expression of the derived 1312-FH2 construct was also very low, but the band 
showed the correct molecular weight, which is slightly higher than the molecular 
weight of FH2. 
 
Figure 12: Western Blot of a formin test expressions. Primary antibody: Mouse anti-HIS. Sizes 
in kDa. Only selected lanes are shown (reshuffled), marker bands are drawn, based on 
markings in the membrane. contr: purified, functional FH2 protein. FH2old: control, expressed 
from the original culture which was used for larger scale expression. FH2-: non-induced, new 
culture. FH2+: induced, expressed from new culture. 1312 FH2+: induced 1312-FH2 construct, 
expressed from new culture.  
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Sequencing results rule out a mutation within the constructs. Some constructs show a 
weak band (Figure 12) of the correct molecular weight Western Blotting. This means 
that the construct itself is not erogenous. 
In some attempts, another strain (E. coli Bl21 Codon Plus RP, i.e. non-DE3) was used 
because expression of the GOI in the PQE-70 vector is driven by a non-T7 promoter. 
For other tried conditions see chapter 4.3. 
One arising hypothesis concerned the high number of prolines in the beginning of the 
constructs. Bases -4 - +37 are particularly sensitive to secondary structure formation 
by mRNA [118]. A high amount of G and C bases (by which proline is coded) is 
particularly unfavourable (personal communication by Sabine Suppmann and Louise 
Rafty, DNA2.0, Menlo Park, CA 94025, USA). However, in construct 1312-FH2, the GC 
content is only 41 % until base 28 and 54% until base 37. This construct and proline-
rich 1228-FH2 have both been expressed by other groups successfully [48]. Moreover, 
even the proline-poor FH2 construct (Figure 12) was not always successfully expressed 
in test expressions performed in our lab or by the Core facility. 
For future expression of the constructs, the following aspects should be considered: 
- The group that developed the expression protocols on which this work is 
largely based recently switched from using HIS-tagged to Maltose-binding-
protein tagged FH2 constructs (personal communication Dr. Kovar). This 
accounts for an unspecific problem grounded in a limited ability of the E. coli 
Bl21 CodonPlus RP strain to express HIS-tagged formin constructs in PQE-70 
vectors. The GOI could be amplified by PCR and subsequently used for SLIC in 
order to test other tags, including maltose-binding tags. All constructs share 
the same 3’ end, and many have a similar sequence at the 5’ end so that the 
number of primers for SLIC cloning would be limited.  
- A mutation in the PQE-70 vector was in discussion as a reason for the occurring 
problems. However, expression of the 1228-FH2 construct (entire FH1 domain) 
also had failed. Cloning of this construct was entirely independent of the other 
experiments; therefore it is unlikely that a mutation in the PQE-70 vector is 
the reason for expression problems. However, the GOI could be transferred 
into a new PQR-70 vector. 
- The “successful” E. coli Bl21 substrain could be stripped of the PQE-70 vector 
with the FH2 construct (using only Chloramphenicol). Then, another PQE-70 
vector with the construct of interest could be transformed into the substrain. 
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2.1.3 Cloning and expression of (P)x-FH2 and (GS)x-FH2 constructs 
Cloning of (P)x and the (GS)x constructs was successful, while expression was not (for   
a discussion see chapter 2.1.2).  
In addition, a “batch” cloning experiment was performed successfully: Different (P)x 
and (GS)x constructs have been generated simultaneously by using a mix of different 
annealed primer pairs. Interestingly, nearly all possible constructs appeared (in 
different colonies) on plate. In order to determine the nature of a specific colony on a 
plate, sequencing was necessary; sequencing of multiple colonies is, however, 
necessary in any case. The purpose of these experiments was to find a simple way to 
later generate mixed (P)x(GS)y-FH2 constructs in a simple batch way. 
The specific procedure would be a two-piece ligation: Digest several (GS)y-FH2 
constructs with SphI and XmaI. Keep the vector, remove the small fragment. Ligate 
the vector with annealed primer pair (ccc)x-1c / ccggg(ggg)x-1catg. 
The obtained construct would then be: 
5’→3’: (…)gcatg|(ccc)x-1c|ccgg(*tc*gg)y-1|gtcccAAATCAAATCAGCTGTAA|CtagtCC(…) 
3’→5’: (…)c|gtac(ggg)x-1gggcc|(*ag*cc)y-1cag|ggTTTAGTTTAGTCGACATTGatc|aGG(…) 
 
Its translation is: M(P)x(GS)yQIKSAV(…) 
 
The GOIs are the same at the beginning and at the end of the construct (exception: 
very small polyproline tracks), therefore these constructs would be good candidates.  
2.1.4 Cloning of Lifeact-FH2 and WH2-FH2 
Neither Lifeact-FH2 nor WH2-FH2 could be cloned. Numerous cloning attempts always 
resulted in mutations, typically leading to a stop codon within the region coding the 
FH2 domain. A very low constitutive expression level of Lifeact-FH2 and WH2-FH2 
might be lethal or highly unfavourable for E. coli. A constitutive expression of 
constructs was also observed in test expressions of FH2, even upon addition of glucose 
in order to reduce “leakiness” of the PQE-70 vector. 
The stop codon was behind the WH2 and Lifeact genes; the expression of these 
peptides alone is obviously not lethal. The FH1-FH2 construct and the FH2 construct 
alone are not lethal for E. coli: Only the spatial or functional proximity of the FH2 
domain and the WH2 rsp. Lifeact domain seems to be highly unfavourable. It could be 
speculated about an interaction of WH2-FH2 or Lifeact-FH2 with a bacterial actin 
analogue.  
 - 30 - 
2.2 Effect of salt on actin polymerization with or without FH2  
2.2.1 Overview 
The impact of salt concentration on FH2 function will be addressed in this chapter. A 
construct containing only the structurally well characterized Bni1p FH2 domain was 
cloned and expressed (see chapter 2.1.2). Pyrene assays and fluorescence microscopy 
were performed at different KCl concentrations. 
 
In a first step (chapter 2.2.2), actin polymerization experiments were performed in 
the absence of FH2 in order to confirm that there is no salt effect on actin 
polymerization present at a salt concentration range between 20 mM <= c(KCl) <= 150 
mM. Outside this concentration range, actin polymerization became slower or did not 
happen. NaCl was added to some assays. Fluorescence microscopy was done for 
different KCl concentrations in order confirm that the filament length distribution is 
the same within this range. 
 
In chapter 2.2.3, similar experiments in the presence of FH2 are shown. The KCl 
concentration was varied between 10 and 90 mM. A salt effect was found. The 
experiments were performed at two different actin concentrations. In order to further 
characterize the salt effect, filament length distribution was measured with 
fluorescence microscopy at different salt concentrations. The filament length 
distribution shows that the FH2 mediated actin nucleation is impeded by KCl in the 
observed concentration range. In some experiments, NaCl was added as a second salt, 
which further reduced polymerization speed. 
 
The experiments were very sensitive on experimental conditions. Several test assays 
were necessary to establish the reaction and protein handling conditions that give the 
most reproducible results (see chapter 4.4 and 4.5 for details). As no TIRF assays were 
performed, numerous parameters were extracted from the pyrene assays as described 
therein. 
 
All conditions and results of the pyrene assays are listed in Table 2. They will be 
discussed in the following two chapters. The product of the pyrene assays was 
sometimes used for further analysis by fluorescence microscopy. 
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Table 2: Pyrene assays – overview of conditions and results. The first three columns show 
the key assay conditions. The experiments are grouped depending on FH2 concentration and 
presence/absence of NaCl. The number of measurements equals to the number of assays done 
under the conditions mentioned in this line. In some cases, fewer measurements (in brackets) 
were used for respective t1/2 and m values (also in brackets). Standard deviations are only 
given when more than 2 datasets were available. kp, m, tlag and t1/2 are results of data analysis 
(see chapter 2.2.3 and chapter 4.5). A single value, two values, or a mean result with a 
standard deviation are given in these columns. The actin concentration was always 3 ± 0.1 mM. 
Pyrene actin concentration was normally 0.59 – 0.60 µM (in assays with NaCl: 0.52 ± 0.02 µM). 
c(FH2) c(KCl) c(NaCl) kp tlag t1/2 m
nM mM mM 10
-4 s-1 s s 10
-4 s-1
0 2 0 2 [0] 0.51, 1.09 1786, 2305 N/A N/A
0 5 0 2 [1] 0.44, 1.13 999, 2886 [7106] [0.60]
0 10 0 2 [1] 0.67, 2.50 620, 2410 [3410] [1.28]
0 20 0 3 3.78 ± 1.22 654 ± 497 2609 ± 1056 1.94 ± 0.61
0 30 0 3 3.55 ± 1.10 499 ± 284 2621 ± 1105 1.80 ± 0.58
0 40 0 2 3.62, 5.04 249, 1495 1609, 3427 1.86, 2.57
0 50 0 9 4.91 ± 1.03 499 ± 445 1989 ± 802 2.51 ± 0.54
0 60 0 5 3.94 ± 0.92 614 ± 377 2389 ± 861 2.01 ± 0.46
0 70 0 4 3.49 ± 1.20 423 ± 279 2610 ± 1072 1.77 ± 0.64
0 80 0 2 3.62, 4.79 380, 626 1839, 2527 2.11, 2.42
0 90 0 10 3.85 ± 0.80 556 ± 172 2453 ± 521 2.02 ± 0.40
0 125 0 5 3.21 ± 0.71 549 ± 161 2812 ± 561 1.68 ± 0.37
0 250 0 4 [3] 2.68 ± 1.11 587 ± 400 [3072 ± 2086] [1.41 ± 0.61]
0 390 0 4 [2] 2.07 ± 1.12 454 ± 117 [2673, 3164] [1.38, 1.61]
0 50 60 1 5.1 243 1565 2.74
0 50 150 2 1.8, 3.5 400, 727 2391, 4578 0.92, 1.85
5.4 40 0 1 79 24 120 41
5.4 50 0 7 76 ± 24 35 ± 16 138 ± 36 38 ± 8
5.4 60 0 2 24, 48 0, 62 224, 258 14, 23
5.4 70 0 3 31 ± 10 75 ± 17 326 ± 76 16 ± 4
5.4 80 0 2 16,38 73, 98 267, 547 9, 16
5.4 90 0 1 16 121 558 7
13.6 10 0 2 192, 211 59, 61 98, 104 71, 76
13.6 20 0 1 97 47 130 47
13.6 30 0 1 144 64 116 61
13.6 40 0 3 74 ± 39 84 ± 13 205 ± 46 32 ± 14
13.6 50 0 5 74 ± 44 58 ± 42 200 ± 55 32 ± 17
13.6 60 0 3 20 ± 5 121 ± 81 479 ± 146 11 ± 3
13.6 70 0 4 24 ± 17 87 ± 57 613 ± 423 12 ± 8
13.6 80 0 3 24 ± 16 140 ± 43 612 ± 420 12 ± 8
13.6 90 0 3 12 ± 6 202 ± 187 872 ± 376 6.0 ± 3.6
13.6 50 15 1 57 120 249 23
13.6 50 60 1 12.1 281 861 6.2
13.6 50 150 2 1.37, 1.98 0, 1000 4459, 4982 0.74, 1.05
Number 
of meas.
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2.2.2 Effect of salt on actin polymerization in the absence of FH2  
Actin polymerization experiments were performed in the absence of FH2 in order to 
confirm that there is no salt effect on actin polymerization at a salt concentration 
range between 20 mM <= c(KCl) <= 150 mM. The conditions of these experiments can 
be found in Table 2. A typical assay with four simultaneous measurements is depicted 
in Figure 13. It is obvious that salt has no impact on actin polymerization in the 
mentioned KCl range. 
kp represents the polymerization constant of the reaction during the elongation phase 
and steady state (for more on these parameters, see chapters 2.2.3 and 4.5). All 
comparable kps are plotted in Figure 14. Below c(Actin) = 20 mM the polymerization 
speed decreases dramatically or polymerization does not take place. At very high salt 
concentrations – up to saturation – actin polymerization speed also declines. The 
results are in agreement with the literature (see chapter 1.3). 
The plot of t1/2 against c(KCl) (Figure 15) confirms these findings.  
Pyrene assays of actin polymerization in the absence of FH2 are difficult to reproduce. 
Therefore usually one will not find different assays from one measurement (multi-cell 
holder) plotted into the same figure. However, plotting of data points derived from 
multiple assays allows the conclusion that there is no relevant salt effect between 
c(KCl) = 20 mM and c(KCl) = 100 mM in the absence of FH2. The critical concentration 
of actin polymerization is around c(KCl) = 10 - 20 mM.  
Fluorescence microscopy (c(Actin) = 3.04 µM, c(PyrActin) = 0.6 µM) confirms that in 
the range between c(KCl) = 40 mM and c(KCl) = 90 mM the distribution of actin 
filament lengths is similar or the same. By visual comparison of microscopy images 
(Figure 16), no major difference between the filament distribution becomes apparent. 
Actin filament length distribution was calculated and fit to exponential functions 
according to chapter 4.6. The fit did not match well the lower filament size, which 
presents no surprise (see chapter 4.6). This was especially the case for c(KCl) = 10 
mM. Therefore, only filaments with a length > 20 px (≈ 1.70 µm) were taken into 
account for the fit. The size distributions and the fits are shown in Figure 17. The size 
distributions between c(KCl) = 40 mM and c(KCl) = 90 mM have similar fit results 
(Figure 18). The distribution at c(KCl) = 10 mM was difficult to fit and might be 
different from the distributions at the other concentrations. This can be attributed to 
the fact that 10 mM is close or slightly below than the critical KCl concentration. 
The absence of a salt effect in this concentration range can be confirmed. 
Addition of high concentrations of NaCl to the solution seems to have the same effect 
on actin polymerization as KCl (Table 2). 
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Figure 13: Actin polymerization in the absence of FH2 at different KCl concentrations 
(pyrene assay). No salt effect observable. Top: raw data, smoothed curve (black) and 
derivatives (smooth coloured lines). Bottom: normalized raw data (coloured) and fits (black). 
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Figure 14: Actin polymerization in the absence of FH2: polymerization speed kp at different 
KCl concentrations. All data can also be found in Table 2. The graph is split for x axis 
compression at higher c(KCl) concentrations. In the concentration range 20-150 mM, there is no 
effect of [KCl] on the polymerization speed visible. 
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Figure 15: Actin polymerization in the absence of FH2: t1/2 at different KCl 
concentrations. All data can also be found in Table 2. The graph is split for x axis compression 
at higher c(KCl) concentrations. In the concentration range ≥ 20 mM, there is no effect of [KCl] 
on t1/2 visible. 
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c(KCl) = 10 mM 
 
c(KCl) = 40 mM 
 
c(KCl) = 60 mM 
 
c(KCl) = 90 mM 
Figure 16: Fluorescence microscopy images of actin filaments at different salt 
concentrations in the absence of FH2. No salt effect is apparent in this concentration range. 
Images are inverted. 
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Figure 17: Actin filament size distributions and fits in the absence of FH2. Fit curves are 
printed in black. Fits were performed only for salt concentrations ≥ 20 px (1 px ≈ 85 nm). No 
salt effect is apparent in this concentration range. 
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Figure 18: Filament size distribution in the absence of FH2, fit results plot. The fit is based 
on the formula y = a * exp(bx). No salt effect is apparent in this concentration range, only the 
a for c(KCl) = 10 mM seems to be low, probably because to the critical KCl concentration (10-
20 mM). 
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2.2.3 Effect of salt on FH2 mediated actin polymerization  
In this chapter, actin polymerization experiments in the presence of FH2 are 
discussed. The KCl concentration was varied between 10 and 90 mM. The experiments 
were performed at two different FH2 concentrations. In order to further characterize 
the salt effect, filament length distribution was measured with fluorescence 
microscopy at different salt concentrations.  
 
The conditions of these experiments can be found in Table 2. A typical assay with four 
simultaneous measurements at c(FH2) = 5.4 nM is depicted at in Figure 19. The 
parameters extracted from all measurements at these FH2 concentrations are plotted 
in Figure 20. More measurements were performed at c(FH2) = 13.6 nM (Figure 21 and 
Figure 22). A KCl range from c(KCl) = 10 nM up to c(KCl) = 90 nm is covered.  
 
There is a salt effect observable in the whole tested c(KCl) range.  
Polymerization speed, described by m and kp, was fastest at the lowest measured KCl 
concentration (10 mM) and slower at the highest measured c(KCl) (90 mM). In the 
experiment with a combined concentration c(KCl) + c(NaCl) = 200 mM, kp was even 
lower. The results for t1/2 confirm these findings. kp represents the elongation phase, 
but depends on nucleation because nucleation determines the number of growing 
filaments. tlag, in contrast, depends on the nucleation phase only. tlag data points also 
show a strong salt effect and therefore point to a salt effect on nucleation (technical 
details on these parameters: chapter 4.6). 
It was not investigated whether the salt effect is specific to KCl. However, in some 
experiments, NaCl was added, and “common” salt concentrations c(KCl) + c(NaCl) up 
to 200 mM were measured (Figure 23). 
For further understanding and confirming the salt effect, fluorescence microscopy was 
performed with c(Actin) = 3.04 µM and c(Pyrene Actin) = 0.6 µM. 
The extent of the salt effect on FH2 mediated actin polymerization became visible 
already during the measurement (Figure 24). 
Actin filament lengths were measured and fit to exponential functions according to 
chapter 4.6. The size distributions and the fits are shown in Figure 25. In Figure 26 the 
fits are results are shown. 
In order to interpret the these distribution fits, it is important to remember that  
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Figure 19: Actin polymerization in the presence of FH2 (5.4 nM) at different KCl 
concentrations (pyrene assay). A salt effect is observable. Top: raw data, smoothed curve 
(black) and derivatives (smooth coloured lines). Bottom: normalized raw data (coloured) and 
fits (black). 
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Figure 20: Effect of [KCl] on actin polymerization at c(FH2) = 5.4 nM. kp and m both 
represent the polymerization speed (depends on elongation and the number of nucleated 
filaments). t1/2 is known as a model-free parameter, which also takes the nucleation phases 
into account. tlag does not depend on elongation. See Figure 22 for similar results at c(FH2) = 
13.6 nM (more data). 
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Figure 21: Actin polymerization in the presence of FH2 (13.6 nM) at different KCl 
concentrations (pyrene assay). A salt effect is observable. Top: raw data, smoothed curve 
(black) and derivatives (smooth coloured lines). Bottom: normalized raw data (coloured) and 
fits (black). 
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Figure 22: Effect of [KCl] on actin polymerization at c(FH2) = 13.6 nM. kp and m both 
represent the polymerization speed (depends on elongation and the number of nucleated 
filaments). t1/2 is known as a model-free parameter, which takes also the nucleation phases 
into account. tlag does not depend on elongation. See Figure 20 for similar results at c(FH2) = 
13.6 nM (more data). 
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Figure 23: Effect of [KCl] and [NaCl] on actin polymerization at c(FH2) = 13.6 nM. The 
polymerization speed kp suggests that the salt effect is also relevant at higher concentrations 
and that it is not limited to KCl. 
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Figure 24: Fluorescence microscopy images of actin filaments at different salt 
concentrations in the presence of FH2. The actin polymerization was FH2 mediated with 
c(FH2) = 13.6 nM. At low concentration, short filaments dominate. At higher KCl 
concentrations, there are fewer and longer filaments. Images are inverted. 
 
 
 
 
 - 43 - 
0
0.01
0.02
0.03
0.04
0.05
15-
25
35-
45
55-
65
75-
85
95-
105
115-
125
135-
145
155-
165
175-
185
length [px]
d
e
n
si
ty
c(KCl) = 10 mM
 
0
0.01
0.02
0.03
0.04
0.05
15-
25
35-
45
55-
65
75-
85
95-
105
115-
125
135-
145
155-
165
175-
185
length [px]
d
e
n
si
ty
c(KCl) = 40 mM
 
0
0.01
0.02
0.03
0.04
0.05
15-
25
35-
45
55-
65
75-
85
95-
105
115-
125
135-
145
155-
165
175-
185
length [px]
d
e
n
si
ty
c(KCl) = 60 mM
 
0
0.01
0.02
0.03
0.04
0.05
15-
25
35-
45
55-
65
75-
85
95-
105
115-
125
135-
145
155-
165
175-
185
length [px]
d
e
n
si
ty
c(KCl) = 90 mM
 
Figure 25: Actin filament size distributions of actin filaments after a pyrene assay with 
c(FH2) = 13.6 nM. Fit curves are printed in black. At low KCl concentration, short filaments 
dominate.  
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Figure 26: Filament size distribution in the presence of FH2 (13.6 nM), fit results plot. The 
fit is based on the formula y = a * exp(bx). The salt effect is significant for both fitting 
parameters. At low concentration, short filaments dominate. At higher KCl concentrations, 
there are fewer and longer filaments. It can be concluded that KCl inhibits FH2 mediated actin 
nucleation rather than blocking elongation. 
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the FH2 domain of Bni1p is known to promote nucleation and slightly block elongation. 
Pyrene assays showed a higher polymerization speed at low KCl concentrations. 
Therefore FH2 could enable a higher polymerization speed by two means: It could 
either promote nucleation even more, or block elongation less. In the first case, lower 
salt should lead to a higher number of small filaments at low concentration; in the 
latter case, the filaments should be longer at low concentrations. 
Size distributions (Figure 26) show that the number of small filaments is higher at a 
low c(KCl). This shows that there is a salt effect on the nucleation activity of the FH2 
domain – salt downregulates nucleation function.  
Exponential can only be accurate if the actin polymerization is close to steady state 
and if annealing and fragmentation are the dominating processes (see chapter 4.6 for 
details on these processes which will be only mentioned shortly in this chapter). A 
non-exponential distribution – in extreme case a peak at higher filament lengths – 
means that these conditions are (still) not realized. However, the fits do match the 
data reasonably well, and the conclusion remains unequivocal. 
It cannot be ruled out that salt blocks the FH2 interaction, also in the sense that FH2 
protects barbed actin ends less from annealing. Therefore there could happen more 
annealing at high salt concentrations. Ring-like structures at higher c(KCl) account for 
the relevance of this phenomenon (Figure 24.d). However, annealing cannot explain 
the higher polymerization speed observed in pyrene assays. The effect of salt on FH2 
nucleation activity is for sure, an effect on annealing might be present on top. 
Considering the location and concentration of FH2, it is not probable that 
fragmentation of actin filaments in the presence differs much from fragmentation in 
the absence of FH2. Fragmentation is known to be promoted by higher salt 
concentrations. If the salt effect would be related to fragmentation, one would 
expect a shift to smaller filaments at higher KCl concentration – the opposite is the 
case. Fragmentation makes the exponential size distribution possible; however, this 
distribution is stable in the beginning, and a significant distribution shift to smaller 
sizes is expected only after several hours. 
c(KCl) = 10-20 mM is the critical concentration for actin polymerization in the absence 
of FH2. Below this concentration, the formation of alternate actin aggregates hinders 
actin nucleation (chapter 1.3). Actin polymerization at c(KCl) = 10 mM is particularly 
fast in the presence of FH2. The formation of aggregates is obviously prevented by 
stabilisation of actin nuclei by FH2. It cannot be ruled out that FH2 promotes actin 
nucleation even in the absence of KCl. 
In yeast, ion concentrations tend to be higher than in typical in vitro experiments 
(chapter 1.3). The few experiments performed with NaCl and KCl suggest that the salt 
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effect is not specific and can be observed also at higher ion concentrations. Due to 
the salt effect found herein, it is recommendable to ensure more realistic salt 
concentrations for in vitro experiments. With higher salt concentrations in vivo, less 
nucleation activity, and eventually more annealing activity is expected. Salt 
concentrations might also have an effect of in vitro and in vivo drug function; in 
attempts to optimize specific FH2 inhibitors (chapter 1.5), salt effects should 
therefore be taken into account. 
A salt effect on nucleation could be explained by reduced electrostatic interaction 
between actin and FH2: salt covering surface charges of these proteins could reduce 
the ability of FH2 to recruit actin for nucleation.  In order to better understand the 
electrostatic nature of the salt effect, computational studies were performed; they 
will be discussed in the next chapter. 
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2.3 Effect of salt on electrostatic binding free energies and 
calculation of solvent accessible surface areas (SASAs) 
The effect of salt on FH2 mediated actin polymerization could in principle be 
governed either by its influence on the FH2 dimer structure itself or by the interaction 
between the FH2 dimer with actin. A reduction of FH2 dimer stability by weakened 
electrostatic interactions at higher salt concentrations would be reasonable; however, 
analytical ultracentrifugation showed in the past that the FH2 dimer is very stable 
even at c(NaCl)=200 mM [57]. An electrophoretic mobility assay confirmed the 
stability of the FH2 dimer [45]. Therefore, electrostatic molecular interactions 
between FH2 and actin are in the focus of this computational approach to the 
problem. The knowledge of the Bni1p FH2 dimer structure [45] (PDB number: 1UX4, 
1UX5) and identification of conserved amino acids on the exposed parts of the FH2 
dimer surface previously led to the identification of two possible regions of 
electrostatic interaction between FH2 and actin [45]. One is located around the apolar 
Ile1431 in the knob region, the other around Lys1601 and Lys1359 [36, 45, 46]. 
Lys1601 residue is located in the post region; Lys1359 is located in the lasso 
subdomain of the other FH2 domain in the dimer. Mutational studies with FH2 domains 
of Daam1 and Bni1p confirmed the functional importance of these and several near 
amino acids for regulation of actin nucleation and elongation [36, 45, 46]. 
A crystal structure of the interaction of an actin molecule with the Bni1p FH2 
molecule is available (PDB number: 1Y64) [36]. In order to comprehensively model a 
salt effect on the nucleation process, it would be necessary to compute different 
protein complexes of two FH2 domains with up to three actin units, similar to 
electrostatic calculations for investigating actin nucleation pathways [17]. In this 
chapter, it will be estimated only how salt could affect the electrostatic interactions 
between FH2 and actin at a specific patch between these two proteins. The 
interaction around Ile1431 in the knob region seems to be of mostly hydrophobic 
nature; in contrast, the interactions around Lys1601 and Lys1359 are probably of 
electrostatic nature [36]. In the mentioned crystal structure, the latter interaction is 
readily available and therefore will be used for calculations. 
Calculations of electrostatic binding free energies have been focused on a region of 
the size 24 Å x 24 Å x 18 Å (10,368 nm3) a in the lasso region of Bni1p (FH2 residues 
1359-1362, Figure 27.a,b). Total electrostatic binding free energies and their Coulomb 
part were calculated for c(KCl) = 10 mM and c(KCl) = 90 mM (c(MgCl2) = 1.05 mM). The 
electrostatic potential was mapped on the surface of the selected region for low and 
high salt conditions (εr = 2, Figure 27.c-f). 
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Figure 27: Electrostatic interaction between actin and a FH2 molecule at the lasso region 
at c(KCl) = 10 mM and c(KCl) = 90 mM. a. Overview of the interaction (1Y64). Green: FH2; 
grey: actin; box: analyzed lasso region. b. Interaction at the lasso region at higher 
magnifications. Colours: see a. Actin amino acids are labelled with a prime. c-f: Surface 
potentials at the lasso interaction site. Blue: positive potential; red: negative potential; actin 
residues: grey; FH2 residues: green. Box: region for which the electrostatic potential has been 
calculated (same as in a and b); c and e (left side): c(KCl) = 10 mM; d and f (right side): c(KCl) 
= 90 mM. c and d: FH2 surface, calculated for FH2 alone.  
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Calculated absolute energies depend strongly on various parameters and do not give 
reliable values; only energy differences are of interest (see chapter 4.7). The total 
electrostatic binding free energy changes upon salt concentration shift: 
∆B∆SaltGelec(Actin, FH2), and their Coulomb part, ∆B∆Salt∆CGelec(Actin, FH2), are listed in 
Table 3 for two different algorithms and several protein dielectrics. The different 
parameters have been chosen because the setting of these parameters is empirical 
(chapter 4.7), and only consistent results at different parameters can be considered 
reliable. ∆B∆SaltGelec(Actin, FH2) is -13.7-15.2 kJ/mol. In other words, the electrostatic 
interaction between actin and FH2 at this specific patch is estimated to be favoured 
at lower salt concentrations. This energy difference is reasonable because it is in the 
energy range of relevant electrostatic protein interactions. It implies a lower KD and a 
lower k-/k+ ratio at lower salt concentrations (formula 1, chapter 1.3). FH2 can 
recruit actin more efficiently at lower salt concentrations because the surface protein 
charges are more exposed and available for electrostatic interaction. The specific 
interaction patch analyzed herein is probably a major contributor to this salt effect on 
electrostatic interaction. 
It might be of interest to estimate which part of this effect can be attributed to 
“direct” electrostatic protein interaction (Coulomb interaction). These results 
(∆B∆Salt∆CGelec(Actin, FH2) in Table 3) show that Coulomb part is the key contributor to 
this effect. It is more negative than the total electrostatic binding free energy, 
pointing to a (slightly) opposing role of the solvent. 
For visualization, the electrostatic potential was calculated not only for this specific 
area in the lasso region, but also for the entire actin protein, the entire FH2 protein 
and the complex of both. The calculation was done for c(KCl) = 90 mM and c(KCl) = 
10 mM; only the CHARMM27 algorithm and εr = 2 were used. Visualizations of the 
resulting electrostatic isosurfaces (at ±1 kT/e) show that the salt effect is evident only  
 
Table 3: Calculation of electrostatic binding free energy changes upon shift from c(KCl) 
from 90 mM to 10 mM at the lasso interaction site. All energies are given in kJ/mol. Energies 
are calculated with five different εr and with two different force field algorithms (A = 
AMBER94, C = CHARMM27). The electrostatic binding free energy ∆B∆Salt∆elecG(Actin, FH2) is 
clearly negative with similar results with different calculation parameters. 
∆B∆Salt∆C∆elecG(Actin, FH2) energies are similar or more negative; electrostatic Coulomb 
interactions are responsible for the salt effect at the lasso interaction site. 
εr(protein)
force field algorithm A C A C A C A C A C
∆B∆SaltGelec(Actin, FH2) -13.7 -14.6 -13.8 -14.6 -14.4 -14.9 -14.8 -15.2 -14.9 -15.2
∆B∆Salt∆CGelec(Actin, FH2) -19.4 -19.9 -16.3 -16.9 -15.4 -15.9 -15.1 -15.5 -15.0 -15.3
121 2 4 8
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   a    b       
 
c 
 
d 
 
 e  f 
Figure 28: Electrostatic isosurfaces of FH2, actin and of the actin-FH2 complex. The arrow 
highlights the lasso interaction region. Blue: positive isosurface (1 kT/e). Red: negative 
isosurface (-1 kT/e). a, b: actin; c, d: FH2; e, f: actin-FH2. Left side (a, c, e): c(KCl) = 10 mM. 
Right side (b, d, f): c(KCl) = 90 mM. 
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in a part of the surface (Figure 28). Some regions in FH2 remain unchanged. Two 
obviously bigger potential changes upon salt concentration shift were localized. One 
of them takes place mainly in the discussed region of interaction at the lasso 
subdomain. The other region is a FH2 dimerization site. At least a part of the 
experimentally discovered salt effect can therefore be attributed to electrostatic 
Coulomb interactions between actin and FH2 at the lasso interaction site. High KCl 
concentrations disrupt this interaction by reducing the surface charge of the 
interacting protein sites. Low KCl concentrations lead to a lower binding free energy, 
to a lower KD and to a lower k-/k+ ratio. This equals to higher actin recruitment by the 
FH2 domain and to increased FH2-mediated actin nucleation. 
 
In order to further evaluate the nature of the lasso interaction site and to understand 
why this electrostatic interaction is so significant, ANCHOR server calculations (Table 
4, experimental details see chapter 4.7) have been performed. They yield ∆SASAs 
(solvent accessible surface areas) and binding energies for individual amino acid 
residues. The amino acid with the biggest ∆SASA is FH2 residue 1362. It is part of the 
lasso interaction site, which has been studied in this chapter. Amino acid at rank 9 
(FH2 residue 1359) is also part of this region. Binding energies calculated by the 
ANCHOR server are favourable only for FH2 residue 1359, unfavourable for FH2 residue 
1360 and neutral for FH2 residue 1362. Actin residues have also different binding 
energies, with low ∆SASAs. However, it has been shown in this chapter that binding 
energies depend on salt concentration and probably also on pH, especially in this 
region. A shift of salt concentration could change the amino acid specific binding 
energy significantly. High ∆SASAs of FH2 residues 1359 and 1360 underline that binding 
energy changes in this region might have a particularly high impact. Amino acids that 
moderate binding energies and high ∆SASAs are possible targets for protein-protein 
inhibitors. In this context, it might be worth recalling Beryllon II, a new FH2 inhibitors 
(chapter 1.5). The compound has a very large surface; due to the big aromatic, sp2 
hybridized system, it is probably flat. It has many negative charges; it is probable that 
it is a protein-protein interaction inhibitor targeting an anchor site at the FH2 
molecule. The lasso interaction site discussed herein is certainly a good candidate. 
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Table 4: Surface accessible surface areas (∆SASA) and interaction energies of amino acids 
in the actin-FH2 complex (1Y64). energy: binding energy calculated by the server, ignoring 
salt and pH contributions. 73 residues had SASA > 0 and are taken into account in this ranking. 
Green highlighting: residues at the lasso interaction area. Anchor regions or residues are 
characterized by a large ∆SASA and negative binding energy.  Due to the large ∆SASA, anchor 
regions can be good drug targets or electrostatic interaction partners even when the binding 
energy per amino acid is not very low. Slightly different salt concentrations might, for 
example, change the binding energy of residues 1362 (∆SASA rank 1) and 1359 (∆SASA rank 9) 
dramatically so that an interaction is more probable.  
chain residue position
/ Å2 rank / kcal/mol rank
FH2 HIS 1362 112.6 1   0.0 40
FH2 GLN 1427 110.5 2   0.4 61
FH2 ILE 1404 108.9 3  -1.3 10
FH2 ILE 1431  84.6 4  -4.0 6
FH2 LYS 1639  83.7 5  -0.5 21
actin GLN 354  67.4 6   1.1 67
actin ASN 128  63.2 7   1.0 66
FH2 LYS 1359  60.8 8  -1.0 11
FH2 LYS 1405  60.7 9  -7.0 1
actin LYS 359  49.6 22   5.2 73
actin GLU 125  35.0 28  -3.1 8
actin ASP 363  28.9 35  -0.4 24
FH2 GLN 1360  25.6 37   1.8 69
actin TYR 362   9.5 56   0.1 44
actin GLN 121   0.8 70   0.0 40
actin TRP 356   0.2 73   0.1 44
∆SASA energy
...
 
 
3 Summary and Outlook 
In this work, structure-function relationships between yeast formin Bni1p and actin 
polymerization were studied. These studies were intended to be based on cloned and 
expressed formin constructs derived from yeast Bni1p (Saccharomyces cerevisiae). In 
the first part of this work, it was attempted to clone and express those formin 
constructs, including the key FH2 domain and a modified FH1 domain. Only the 
expression of the FH2 domain was successful. This construct was used in the second 
part of the work, which focused on a previously unknown effect of the KCl 
concentration on the FH2 mediated actin nucleation. 
 
Cloning and expression of the yeast Bni1p FH2 domain in E. coli was successful. 
Molecular cloning of other derived constructs with a polyproline track and cloning of 
the 1228-FH2 (FH1-FH2) construct were also successful. However, only some of these 
constructs were expressed in traces. (P)x-FH2 constructs with one polyproline track of 
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variable length and (GS)x-FH2 constructs with one polyproline track and a variable 
linker between the track and the FH2 domain have been cloned in a batch approach. 
This batch cloning approach could be useful in order to find a way for cloning multiple 
constructs of the type (P)x-(GS)y-FH2. (P)x-FH2, (GS)x-FH2 and combined constructs 
would be easy to model for several reasons: The interaction of profilin with 
polyproline is characterized well, the (GS)y linker follows a wormlike chain model and 
FH2 crystal structures are known. Models involving both diffusion and concentration-
limited actin recruitment kinetics could be tested with such proteins. 
The attempt to clone FH2 constructs with attached G-actin binding proteins (Lifeact, 
WH2) was unsuccessful. Stop mutations within the FH2 domain point to a very 
unfavourable effect of these combined constructs, but not Lifeact, WH2 or FH2 alone, 
on E. coli. One may speculate about a functional interaction of these constructs with a 
protein similar to eukaryotic actin. 
 
Pyrene assays and epifluorescence microscopy revealed a salt effect on FH2 mediated 
actin nucleation, implying that electrostatic interactions play a major role in this 
process. A detailed protocol for achieving reproducible pyrene assays was developed. 
The salt effect is clearly significant in two measurement series with different FH2 
concentrations and was investigated for a potassium chloride (KCl) concentration 
range between 10 mM and 90 mM. Control experiments without FH2 confirm that the 
salt effect relates to FH2 function. KCl turned out to be a downregulator of FH2 
nucleation activity in this concentration range. A higher KCl concentration leads to a 
significantly lower actin polymerization speed (kp, m) and to a bigger lag time (tlag) 
and bigger t1/2. In terms of actin filament length distribution, a higher KCl 
concentration leads to longer and fewer filaments. Experimental data show that the 
critical KCl concentration is lowered in the presence of FH2 (if not 0). Some initial 
experiments with sodium chloride were done in this work; they point to a relevance of 
this salt effect also at salt concentrations >> 100 mM. Further work is necessary to 
prove that the discovered salt effect is not salt-specific. In the future, this salt effect 
should be considered in in vitro experiments on formins. For example, in vitro 
screening for FH2 inhibitors should preferably take place at salt concentrations which 
mimic in vivo conditions. 
Computational studies were performed to investigate the electrostatic nature of the 
salt effect further. Electrostatic surface potential and binding free energy changes 
upon salt concentration change within a known actin-FH2 complex (1Y64) were 
calculated. A decrease of the KCl concentration leads to lower binding free energies. 
This is especially the case for one specific interaction site (lasso site) which was 
 - 53 - 
discussed as an important electrostatic interaction site in the literature. The binding 
free energy at this site is predicted to drop by 13.7-15.2 kJ/mol upon change of c(KCl) 
from 90 mM to 10 mM due to increased electrostatic Coulomb interactions. Salt leads 
to a reduction of surface charges necessary for electrostatic FH2-actin interaction. 
ANCHOR calculations of solvent accessible surface areas (SASAs) show that this site 
might be a candidate for protein-protein interaction inhibitors. It would not be 
surprising if one of the existing inhibitors, for example Beryllon II, interacts with this 
particular site. In the future, mutational studies at this and other interaction sites 
could reveal where the inhibitor binds. It would then be possible to predict whether 
an inhibitor binds to a specific isoform or not by structural comparison of homology 
models. High SASAs of residues HIS1359 and LYS1362 explain why the lasso interaction 
site plays a crucial role in the electrostatic FH2-actin interaction and why the 
interaction might be sensitive to salt concentration shifts.  
 
The experimentally found downregulation of FH2 mediated actin nucleation by KCl can 
therefore be explained by reduced actin recruitment by the FH2 dimer: KCl diminishes 
the surface charge of FH2 and actin and thus weakens electrostatic Coulomb 
interactions. The lasso interaction site is probably affected in particular, with a drop 
of the electrostatic binding free energy upon reduction of KCl concentration and high 
solvent accessible surface areas (SASAs) at residues HIS1359 and LYS1362. The salt 
effect is probably a non-specific salt effect. Results of this work suggest that the 
presence of FH2 lowers the critical KCl concentration; the new critical KCl 
concentration – if there is any - remains to be determined. Elongation and nucleation 
rates could be determined by TIRF measurements in the future. The relevance of this 
new salt effect in vivo remains to be demonstrated. 
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4 Experimental 
4.1 Materials 
4.1.1 Enzymes, proteins and chemicals 
 
Enzymes 
 
Phusion High Fidelity DNA Polymerase    Biolabs 
Pfu DNA Polymerase      Fermentas 
Restriction enzymes     Biolabs, Fermentas, Promega 
cOmplete™, Mini Protease Inhibitor Cocktail Tablets  Roche 
Taq DNA Polymerase      Biolabs 
T4 DNA Ligase       Biolabs 
 
These enzymes are often accompanied by buffers, packed as a Kit. These buffers and 
Kits are not listed explicitly in chapters 4.1.2 and  4.1.3. 
 
Proteins 
 
Bovine Serum Albumin    Sigma 
Acetone Powder (Chicken skeletal muscle) Lab collection (A. Crevenna) 
Pyrene Actin     Lab collection (A. Crevenna) 
Mouse anti-His antibody   Core Facility collection / former Nigg lab 
Goat anti-mouse antibody   Biorad (Cat. No. 170-5047) 
 
Expression of formin constructs is explained in chapter 4.3. Purification of actin from 
Chicken Acetone Powder is described in chapter 4.4. 
 
Chemicals 
 
Ampicillin (sodium salt)    Roche (Core Facility: Roth) 
ATP-NA      Roche 
Chloramphenicol    Fluka (Core Facility: Serva) 
DTE      Serva 
DTT       Biomol 
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Synperonic® (cat. no. 15976)   Erbslöh 
Tryptone      Bacto 
Yeast Extract     BioSpringer or Bacto 
other standard laboratory chemicals   Merck, Roth and Sigma Aldrich  
4.1.2 Kits, vectors and strains 
Agarose Gel Extraction Kit (Jena Bioscience) for isolation of DNA fragments 
 
CloneJet™ Kit, Fermentas 
 
E.Z.N.A.® (Omega Bio-Tek) Plasmid Mini Kit 
 
SimplyBlue™ SafeStain Kit (Invitrogen) for staining SDS gels 
 
pJET1.2/blunt cloning vector (Fermentas) for molecular cloning of PCR products (part 
of the CloneJet™ Kit, Fermentas) 
 
pQE70 vector (Quiagen, expression vector) 
 
Genomic DNA from Saccharomyces cerevisiae wild type strain S288C, from lab 
collection 
 
One Shot® TOP10 Chemically Competent E. coli (part of the TOPO® TA Cloning® Kit, 
Invitrogen) for molecular cloning of PCR products.  
Genotype: F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG  
 
E.coli Bl21-CodonPlus®(DE3)-RP strain (Stratagene) for expression 
Genotype: E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte [argU proL 
Camr] 
 
E.coli Bl21-CodonPlus®-RP strain (Stratagene) for expression 
Genotype: E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal endA Hte [argU proL Camr] 
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4.1.3 Buffers, media and solutions 
 
Blotting transfer buffer 
 
50 mM tris base 
40 mM glycin 
20% (v/v) methanol 
 
Collection gel buffer 
 
12.6% (v/v) 1M tris-HCl 
10% (v/v) acrylamide/bisacrylamide 37.5%/1.4% (w/v) 
0.1% (w/v) SDS 
pH 6.8 
 
DNA loading buffer 6x 
 
in TE buffer 
50 % (w/v) sucrose 
0.25% (w/v) bromophenol blue 
 
Formin elution buffer 
 
modification of Lysis buffer 3: 250 mM imidazol instead of 10 mM imidazol 
 
Formin expression medium 1 
 
in liquid YT medium 
33 mM MgSO4 x 7 H2O 
1% (w/v) Ampicillin 
0.34% (w/v) Chloramphenicol 
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Formin expression medium 2 
 
liquid YT medium 
4% (v/v) glycerol 
0.01% (v/v) Synperonic 
5.74 mM K2HPO4 x 3 H2O 
33 mM MgSO4 x 7 H2O 
 
34 µg/ml Chloramphenicol 
100 µg/ml Ampicillin 
pH = 7 
 
Formin gel filtration & storage buffer 
 
20 mM HEPES  
200 mM NaCl 
10% (v/v) Glycerol 
1 mM EDTA 
1 mM TCEP 
pH = 7.4 
 
Formin washing buffer 
 
modification of Lysis buffer 3: 20 mM imidazol instead of 10 mM imidazol 
 
G buffer (degassed, stored at 4°C) 
 
2 mM tris-HCl 
0.1 mM CaCl2 
0.2 mM ATP 
0.5 mM DTT 
pH = 8.0 
 
KMEI buffer (10x) 
 
10 mM MgCl2 
10 mM EGTA 
100 mM imidazole 
100 mM – 900 mM KCl (variable) 
pH = 7.0 
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Laemmli buffer (typical composition) 
 
63 mM tris-HCl  
4% (v/v) SDS  
10% (v/v) glycerol 
10% (v/v) mercaptoethanol  
0.025‰ (v/v) Bromophenol Blue 
pH = 6.8 
 
Lysis Buffer 1 
 
50 mM NaH2PO4 
500 mM NaCl 
10% (v/v) glycerol 
10 mM mercaptoethanol or 1 mM TCEP 
10 mM imidazol 
5 mM MgCl2 
1% (v/v) protease inhibitor solution with 
1 mM AEBSF-HCl 
0.1% (w/v) Pepstatin 
0.1% (w/v) Leupeptin 
0.2% (w/v) Aprotinin 
0.1% (w/v) DNAse 
or Roche cOmplete™, Mini Protease Inhibitor Cocktail Tablets  
pH = 8 
 
Lysis buffer 2  
 
100 mM HEPES 
500 mM NaCl 
10 mM imidazol 
1% (v/v) protease inhibitor solution with 
1 mM AEBSF-HCl 
0.5% (w/v) Pepstatin 
0.25% (w/v) Leupeptin 
0.2% (w/v) Aprotinin 
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Lysis Buffer 3 
 
50 mM NaH2PO4 
500 mM NaCl 
10% (v/v) glycerol 
10 mM imidazol 
5 mM MgCl2 
1% (v/v) protease inhibitor solution with 
1 mM AEBSF-HCl 
0.1% (w/v) Pepstatin 
0.1% (w/v) Leupeptin 
0.2% (w/v) Aprotinin 
0.1% (w/v) DNAse 
pH = 8 
 
ME buffer (10x) 
 
0.5 mM MgCl2 
2 mM EGTA 
pH = 8.0 
 
PBS buffer 
 
140 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
pH 7.3-7.4 
 
PBS-T buffer 
  
 in PBS buffer 
0.5% (v/v) Tween 20 
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RF1 buffer 
 
100 mM RbCl 
50 mM MnCl2 
30 KOAc 
10 mM CaCl2 
15% (w/v) glycerol 
pH = 5.8 
 
RF2 buffer 
 
10 mM MOPS 
10 mM RbCl 
75 mM CaCl2 
 
SDS running buffer 
 
25 mM tris 
192 mM glycine 
0.1% (w/v) SDS 
 
Separation gel buffer 
 
37.5% (v/v) 1 M tris-HCl 
25% (v/v) acrylamide/bisacrylamide 37.5%/1.4% (w/v) 
0.1% (w/v) SDS 
pH = 8.8 
 
Solution A 
 
0.1 M Tris-HCl 
1.4 mM Luminol 
pH = 8.0 – 8.6 
 
Solution B 
 
solvent: DMSO 
6.7 mM p-coumaric acid 
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TBE buffer 10x 
 
440 mM tris base 
440 mM boric acid 
10 mM EDTA 
pH = 8.0 
 
TE buffer 10x 
 
10 mM tris base 
1 mM EDTA 
pH = 8.0 
 
Terrific Broth medium 
 
1.2% (w/v) Bacto Tryptone 
2.4% (w/v) Bacto Yeast Extract 
0.4% (v/v) glycerol 
17 mM KH2PO4 
72 mM K2HPO4 
 
Tris buffer 1M 
 
619 mM tris-HCl 
381 mM tris Base 
pH = 8.0 
 
YT medium 
 
0.8% (w/v) Bacto Tryptone 
0.5% (w/v) Bacto Yeast Extract 
0.5% (w/v) NaCl 
often with 100 µg/ml (alternative: 400 µg/ml Ampicillin)  
often with 34 µg/ml Chloramphenicol 
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4.1.4 Oligonucleotides 
Oligonucleotides were obtained from Metabion, Martinsried. All oligonucleotides are 
printed in 5’→3’ direction. Sticky ends of aligned primers are highlighted. Code 
that coincides with the code of the “wild type” formin gene is capitalized.  
Important: Restriction sites BamHI, SphI, SpeI, NgoMIV, XmaI and PpuMI. XmaI and 
NgoMIV are compatible. 
 
Primers for cloning from genomic DNA 
 
FH2 
forward primer: gcatgCAAATCAAATCAGCTGTAACtagtCCATTACTTCCTCAATCGCC 
reverse primer: ggatccTTCTTCCACTATTTTCTTATGC 
 
 
1228-FH1FH2    
forward primer: gcatgCTCagTACTCAATCATCTGTACTCTCCT 
reverse primer: ggatccTTCTTCCACTATTTTCTTATGC 
 
 
Oligonucleotides for the modification of the FH2 construct (first modification 
iteration) 
 
Lifeact-FH2  
forward: ATGGGTGTCGCAGATTTGATCAAGAAATTCGAAAGCATCTCAAAGGAAGAAGCta 
gcCAAATCAAATCAGCTGTAA 
reverse: ctaGTTACAGCTGATTTGATTTGgctaGCTTCTTCCTTTGAGATGCTTTCGAATT 
  TCTTGATCAAATCTGCGACACCCATcatg 
 
WH2-FH2  
forward: tcaggaaacaaagcagctcttttggatcaaattagagagggtgctcagctgaaaa 
aagtggaacagaacgcgtcgCAAATCAAATCAGCTGTAA 
reverse: ctaGTTACAGCTGATTTGATTTGcgacgcgttctgttccacttttttcagctgag 
caccctctctaatttgatccaaaagagctgctttgtttcctgacatg 
1321-FH1FH2 
forward: CCGCCgGCgCCACCTATGATGCCGGCtagcCAAATCAAATCAGCTGTAA 
reverse: ctaGTTACAGCTGATTTGATTTGgctaGCCGGCATCATAGGTGGcGCcGGCGGcatg 
 
1312-FH1FH2 
forward: cTATCTTCATCTACTGATGGCGTCATTCCGCCgGCgCCACCTATGATGCCGGC 
tagcCAAATCAAATCAGCTGTAA 
reverse: ctaGTTACAGCTGATTTGATTTGgctaGCCGGCATCATAGGTGGcGCcGGCGG 
AATGACGCCATCAGTAGATGAAGATAgcatg 
(P)4-FH2 
forward: ccacctccgccggctagcCAAATCAAATCAGCTGTAA 
reverse: ctaGTTACAGCTGATTTGATTTGgctagccggcggaggtggcatg 
 
(GS)3-FH2 
forward: ccaccgcctcctccgcccgggtcaggttctgggtcccAAATCAAATCAGCTGTAA 
reverse: 
ctaGTTACAGCTGATTTGATTTgggaanatcccagaacctgacccgggcggaggaggcggtggcatg 
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Oligonucleotides for the modification of the (P)4-FH2 construct (second 
modification iteration) 
 
(P)6-FH2 
forward: ccaccgcctcctccg 
reverse: ccggcggaggaggcggtggcatg 
 
(P)8-FH2 
forward: ccgccaccaccaccaccaccaccaGCtagcCAAATCAAATCAGCTGTAA 
reverse: ctaGTTACAGCTGATTTGATTTGgctaGCtggtggtggtggtggtggtggcggcatg 
 
(P)10-FH2  
forward: ccaccgcctccacctccg 
reverse: ccggcggaggtggaggcggtggcatg 
 
(P)12-FH2 
forward: ccacctccaccaccgccaccgcctccacctccg 
reverse: ccggcggaggtggaggcggtggcggtggtggaggtggcatg 
 
(P)14-FH2 
forward: ccaccgcctccacctccaccgccgcctccacctcctccg 
reverse: ccggcggaggaggtggaggcggcggtggaggtggaggcggtggcatg 
 
 
Oligonucleotides for the modification of the (GS)3-FH2 construct (second 
modification iteration) 
 
(GS)6-FH2 
forward: ccgggtcaggtagtggatcgggttccggctctgg 
reverse: gacccagagccggaacccgatccactacctgac 
 
(GS)9-FH2  
forward: ccgggtcaggtagtggatcgggttccggctctggaagtggctcaggttctgg 
reverse: gacccagaacctgagccacttccagagccggaacccgatccactacctgac 
 
(GS)12-FH2 
forward: ccgggtcaggtagtggatcgggttccggctctggaagtggctcaggtagcggttccggtag 
tggatctgg 
reverse: gacccagatccactaccggaaccgctacctgagccacttccagagccggaacccgatccac 
tacctgac  
(GS)15-FH2 
forward: ccgggtcaggtagtggatcgggttccggctctggaagtggctcaggtagcggttccggtag 
tggatcgggaagtggttcaggctctgg 
reverse: gacccagagcctgaaccacttcccgatccactaccggaaccgctacctgagccacttccag 
agccggaacccgatccactacctgac 
 
Sequencing primers 
 
1) Primers included in the CloneJet™ Kit, Fermentas 
2) Self-designed sequencing primers: 
Internal FH2 reverse primer  gattttgacaaaaactcaac 
PQE-70 forward primer  gctttgtgagcggataacaa 
PQE-70 reverse primer  ggatctatcaacaggagtccaa 
 
 
 - 64 - 
4.2 Molecular cloning 
4.2.1 General procedure 
Molecular cloning experiments followed generally the following procedure: 
A PCR of genomic DNA (protocol see below) was performed in order to yield the gene 
of interest (GOI). Primers for either the FH2 or the 1228-FH1FH2 construct were used. 
After running a standard Agarose gel electrophoresis (protocol see below), the GOI 
was cut out under UV illumination and extracted (Agarose Gel Extraction Kit, Jena 
Bioscience). The PCR product was ligated into a PJET 1.2/blunt vector (Fermentas, 
protocol see below), then transformed to an E. coli TOP10 strain (protocol see below) 
and grown overnight on YT/Amp plates at 37°C. The next day, 2-12 colonies were 
picked and grown in liquid YT/Amp (200 rpm shaking) overnight at 37°C. Plasmids 
were then isolated using E.N.Z.A. Plasmid Miniprep Kit (Protocol I). This protocol was 
slightly adapted specifically to the amount of processed YT medium. A part of the 
isolated DNA was used for sequencing (protocol see below), the other part was double 
digested with SphI (HF) and BamHI; the smaller fragment was isolated (Agarose gel, 
then extraction) and ligated into a PQE-70 vector (protocol see below), which also had 
been double digested with SpHI + BamHI. The PQE-70 vector with the construct was 
transformed into an E. coli TOP10 strain (protocol see below). It was grown overnight; 
2-12 colonies were picked and grown in liquid YT/Amp overnight. For storage at -
80°C, the liquid culture was mixed with the same volume of glycerol (50%) and flash 
frozen. Plasmids were then isolated as described above. These genomic cloning 
experiments yielded the FH2 construct and the 1228-FH1FH2 construct. 
The plasmids (GOI in PQE-70 vector) were then transformed into the E. coli Bl21 
compatible expression strain (protocol see below). It was grown as described above, 
but Chloramphenicol was added to the medium in order to keep the pACYC-based 
plasmid containing extra copies of the argU and proL tRNA genes. 
Alternatively, the GOI was modified in order to yield other constructs. For this, it was 
double digested with enzymes cutting specifically inside the gene. Two annealed 
primers were ligated directly to the isolated digestion product (protocol see below). 
These primers were in big parts complementary, with their sticky ends matching the 
sticky ends of the digestion product. The further proceeding (starting at 
transformation of the PQE-70 vector into the E. coli TOP10 strain) was the same as 
above. 
These modification steps were performed iteratively in order to yield other, more 
complex constructs. 
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The first iteration was based on the FH2 construct: 
Beginning of the FH2 construct sequence (the construct is embedded in a PQE-70 vector) 
 
5’→3’: gcatg|CAAATCAAATCAGCTGTAA|CtagtCCATTACTT(…) 
3’→5’: c|gtacgTTTAGTTTAGTCGACATTGatc|aGGTAATGAA(…) 
 
Digestion of FH2 with Sph1 and Spe1, ligation with primers 
 
The following constructs were derived from this FH2 constructs with the corresponding 
primers: 
Lifeact-FH2, WH2-FH2, 1321-FH1FH2, 1312-FH1FH2, (P)4-FH2, (GS)3-FH2 
 
 
One second iteration was based on the (P)4-FH2 construct: 
     Beginning of the (P)4-FH2 construct sequence (embedded in a PQE-70 vector) 
 
5’→3’: gcatg|ccacctccg|ccggctagcCAAATCAAATCAGCTGTAA|CtagtCCATTACTT(…) 
3’→5’: c|gtacggtggaggcggcc|gatcgGTTTAGTTTAGTCGACATTGatc|aGGTAATGAA(…) 
 
Digestion of (P)4 with Sph1 and NgoMIV (compatible with XmaI), ligation 
with primers. Only (P)8-FH2: Digestion of (P)4 with Sph1 and Spe1. 
 
The following constructs were derived from these FH2 constructs with the 
corresponding primers: 
(P)6-FH2, (P)8-FH2, (P)10-FH2, (P)12-FH2, (P)14-FH2  
 
 
Another second iteration was based on the (GS)3-FH2 construct: 
Beginning of the (GS)3-FH2 construct sequence (embedded in a PQE-70 vector) 
 
5’→3’: gcatg|ccaccgcctcctccgc|ccgggtcaggttctgg|gtcccAAATCAAATCAGCTGTAA|CtagtCC  
3’→5’: c|gtacggtggcggaggaggcgggcc|cagtccaagacccag|ggTTTAGTTTAGTCGACATTGatc|aGG  
 
Digestion of (GS)3 with XmaI (compatible with NgoMIV) and PpuMI, ligation 
with primers; other digestion sites in this construct: Sph1, Spe1.  
 
The following constructs were derived from this FH2 constructs with the corresponding 
primers: 
(GS)3-FH2, (GS)6-FH2, (GS)9-FH2, (GS)12-FH2, (GS)15-FH2 
 
Many constructs of the second modification iterations were yielded by the batch 
variation of this procedure (see below). 
 
All constructs were sequenced, and test digestions were performed repeatedly during 
the procedures. All constructs have a HIS-tag at their C-terminal end. 
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4.2.2 Specific technical protocols 
The following technical protocols are listed in this chapter: 
 
Agarose gel electrophoresis 
Construct modification 
Construct modification (batch modification) 
(Double) digestions 
E. coli cell density measurements 
Ligation of DNA into a PQE-70 plasmid 
Ligation of PCR products into a PJET 1.2 vector 
Polymerase chain reaction 
Preparation of competent E. coli 
Sequencing 
Transformation of E. coli strains and plating 
 
Agarose gel electrophoresis 
 
DNA fragment separation was done by standard agarose gel electrophoresis with a 
standard 1% agarose gel in TBE buffer. A GeneRuler™ DNA ladder mix was used. The 
electric field (100-150V) was applied for 30-45 minutes. Gels were photographed with 
a GeneFlash gel imaging system (Syngene Bio Imaging). 
 
Construct modification  
 
In this procedure, a gene (“old gene of interest”) in a PQE-70 vector is partially 
substituted by two annealed, partially complementary primers. 
A part of the “old gene of interested” is first removed from the PQE-70 vector by 
double digestion.  
For annealing of the two partially complementary primers, 49 µl ddH2O were mixed 
with 0.5 µl of the forward and 0.5 µl of the reverse primer (alternative: 46 µl H2O and 
2 µl of each primer). The mixture was heated to 95°C in a Thermo Electron PxE 0.2 
ThermoCycler for 10 minutes. Then it was cooled stepwise (each step 4 minutes): 90 
°C, 85 °C, 80 °C, 78 °C, 76 °C, 74 °C, 72 °C, 70 °C, 69 °C, 68 °C, 67 °C, 66 °C, 65 
°C, 64 °C, 63 °C, 62 °C, 61 °C, 60 °C, 58 °C, 57 °C, 56 °C, 55 °C, 53 °C, 51 °C, 49 
°C, 47 °C, 45 °C, 43 °C, 40 °C, 35 °C, 30 °C, 25 °C. The mixture then was hold at 
4°C. It was then diluted 1:10 (alternative: no dilution). 
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For ligation of these annealed primers with the PQE-70 vector, 6.5 µl (alternative: 5 
µl) double digested cleaned PQE-70 vector with the partial “old gene of interest”, 1.5 
µl of the annealed primer solution (alternative: 3 µl), 1 µl ligase buffer and 1 µl ligase 
were mixed and  kept overnight at 16°C. 
 
Construct modification (batch modification) 
 
The preceding protocol was varied for a batch approach to get several modifications 
of the construct simultaneously. 
Variations of the preceding protocol for the batch approach: 
- Initially, 46 µl H2O are mixed with 2 µl of each primer. 
- After primer annealing (“hold at 4 °C”): Instead of dilution prepare a mix of several 
annealed primers and continue as if it were a single experiment with only one 
annealed primer. The use of the resulting library is further explained and discussed in 
the results part. 
 
(Double) digestions 
 
For digestions and double digestions, recommendations by NEB were followed (NEB 
online Double Digest Finder), even when the restriction enzyme was not purchased 
from NEB. 
 
E. coli cell density measurements 
 
E. coli cell densities in liquid culture were measured with a GeneSys 
spectrophotometer (Thermo Electron) at λ = 600 nm (OD600 = 1 corresponds to ≈ 109 
cells/ml). 
 
Ligation of DNA into a PQE-70 plasmid 
 
6 µl of double digested DNA, 2 µl of double digested PQE-70 vector, 0.5 µl T4 ligase 
and 1 µl ligase buffer were mixed and kept 3 hours at room temperature or (in 
difficult cases) overnight at 16°C 
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Ligation of PCR products into a PJET 1.2 vector 
 
0.5 µl PJET 1.2 vector, 0.5 µl T4 ligase and 1 µl ligase buffer were mixed with 5 µl 
ddH2O and kept for 20 minutes at room temperature. 
 
Polymerase chain reaction 
 
A PCR mix (36.5 µl ddH2O, 1 µl dNTP mix, 1 µl genomic DNA, 0.5 µl of each primer, 10 
µl Herculase or Pfu Polymerase buffer) was pre-heated for 8 minutes to 95°C. After 
adding 1 µl of Herkulase DNA Polymerase or Pfu DNA Polymerase, the mix was heated 
for further two minutes.  A Thermo Electron PxE 0.2 ThermoCycler to run 32 cycles of 
the following programme: 
  1 minute Denaturation: 95°C 
  1 minute Annealing temperature (58 or 60 °C) 
  1.5 minutes Synthesis: 72°C 
Afterwards the mixture was kept at 72°C for 10 minutes and then hold at 4 °C. 
 
Preparation of competent E. coli 
 
E. coli cultures from agar plates were grown in 5 ml YT medium over night at 37°C. 50 
ml YT medium were inoculated with 1 ml of the liquid culture and grown until OD600 ≈ 
0.5. The cultures and all necessary equipment were cooled and then centrifuged at 
3000 rpm in a precooled Biofuge Primo R (Thermo Scientific) for 15 minutes. The 
pellet was resuspended with cooled RF1 (33 ml) and cooled 45 minutes on ice. Cells 
were harvested again and resuspended with cooled RF2 (5 ml). After incubation on ice 
for 15 ml, the cells were aliquoted and shock frozen for storage at -80°C.  
 
Sequencing 
 
For sequencing, 3 µl of the plasmid with the GOI were mixed with 3.5 µl ddH2O and 
1 µl of the sequencing primer. For pJET 1.2/BLUNT vectors, the supplied sequencing 
primers were used; in one case, an internal FH2 reverse primer was needed for 
complete sequencing. Modified constructs were sequenced directly from the PQE-70 
vectors. Sequencing was not very efficient in those cases, therefore 6.5 µl of the 
plasmid with the GOI sometimes were supplied instead of water. Sequencing primers 
for the PQE-70 vector were designed (chapter 4.1.4). The internal FH2 reverse primer 
mentioned above was also used for sequencing constructs in the PQE-70 vector. 
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The sequencing reactions were carried out by the Core Facility of Max-Planck Institute 
of Biochemistry using an ABI-3730 (Perkin Elmers) sequencer and ABI Big Dye 3.1 
sequencing chemistry.  
 
Transformation of E. coli strains and plating 
 
2 µl non-PCR plasmid or 10 µl of freshly ligated PCR product were added to 50 µl  
E. coli competent cells on ice and carefully mixed. After 30 minutes, the mixture was 
heated to 42°C for 2 minutes and then put on ice for another 2 minutes. After 
addition of 150 µl YT medium, it was waited further 2 minutes. The mixture was 
plates on a YT plate with antibiotic(s). The culture grown over night at 37°C. 
 
Choice of antibiotic(s) + strains 
For sequencing of GOI in PJET 1.2 vector: E. coli TOP10 strain; Ampicillin 
For amplification of PQE-70 vector with construct: E. coli TOP10 strain; Ampicillin 
For expression of GOI in PQE-70 vector: E. coli Bl21-CodonPlus (DE3) RP strain; 
 Ampicillin + Chloramphenicol. A DE3 and a non-DE3 strain were used. 
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4.3 Expression of formin constructs 
All expression procedures are based on similar protocols for expression of similar 
constructs [48, 60]. 
 
Test expressions (own laboratory) 
 
An E.coli Bl21-CodonPlus®(DE3)-RP strain or an E.coli Bl21-CodonPlus®-RP strain with 
the construct of interest in a PQE-70 vector was grown from plate culture. As a 
control, strains with empty PQE-70 vectors or strains with no PQE-70 vectors (no 
Ampicillin) were used. The liquid medium was YT medium with 100 µg/ml 
(alternative: 400 µg/ml Ampicillin) and 34 µg/ml Chloramphenicol. At an OD600  of ≈ 4 
(absolute), [30 µl / OD600] of the sample were transferred into 3 ml of fresh medium. 
Induction was started ≈ 3 hours later. Induction time was variable (f.e. 12, 16 or 24 
hours), induction temperatures were 16 °C, 24 °C and 37 °C. IPTG concentration was 
0.5 mM. [150 µl / OD600] of the sample were spun down (VWR Galaxy 16 DH, 11000 g, 1 
min). 
For a SDS-PAGE analysis without subsequent Western Blotting the pellet was mixed 
with 25 µl Laemmli buffer (1x) and shortly (5 min) heated to 95 °C for lysis. After 
cooling and spinning down (VWR Galaxy 16 DH, 11000 g, 1 min) cellular debris, the 
supernatant was used for molecular weight determination by SDS-PAGE. 
For a SDS-PAGE analysis with subsequent Western Blotting the pellet was first lysed 
with 25 µl of lysis buffer 1 (with mercaptoethanol). Both buffer variations (different 
protease inhibitor combinations) were tested. Subsequently, 25 µl of the solution were 
mixed with 25 µl Laemmli buffer. After spinning down (VWR Galaxy 16 DH, 11000 g, 1 
min) cellular debris, the supernatant was used for molecular weight determination by 
SDS-PAGE and Western Blotting. 
The gel for SDS-PAGE was composed of a 10% separation gel (9.9 ml separation gel 
buffer, 75 µl 10% APS, 5 µl TEMED) and a 4% collection gel (5 ml collection gel buffer, 
25 µl 10% APS, 5 µl TEMED). SDS running buffer, 8 µl of PageRuler Prestained Protein 
Ladder and 10 µl of each sample in Laemmli buffer were used to perform the SDS-
PAGE. Subsequently, the gel was either stained with the SimplyBlue™ SafeStain Kit or 
submitted to Western Blot analysis. 
For Western blotting, a standard Semi Dry Blot was performed for transfer on a 
nitrocellulose membrane (Blotting transfer buffer). The positions of the protein ladder 
bands (determined by staining with Ponceau S) were marked by piercing the 
membrane. The membrane was blocked with PBS-T containing 0.5% BSA over night. 
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Washing buffers were PBS-T buffer or PBS buffer. Antibodies were diluted with PBS-T 
containing 0.5% BSA. The first antibody was mouse anti-HIS IgG (0.05% v/v), the 
second antibody was HRP-linked goat anti-mouse IgG (0.033% v/v). A 
chemilumescence reaction was performed by incubating the membrane with a mixture 
of 6 ml solution A, 60 µl solution B and 1.8 µl H2O2 (30%) for 1 minute. Luminescence 
images were recorded with a Fujifilm LAS-300 imaging system. 
 
Other test expression experiments and large scale production of FH2 was performed 
by the Core Facility of the Max Planck Institute for Biochemistry. The procedures were 
discussed and modified extensively; therefore they are described in the following. 
 
Test expressions (Core Facility of the Max Planck Institute for Biochemistry) 
 
The FH2 construct was test expressed following this protocol: 
An E.coli Bl21-CodonPlus®(DE3)-RP strain with the FH2 construct in a PQE-70 vector 
from plate culture was induced to express the construct. Formin expression medium 1 
was used; IPTG concentration for induction was 0.4 mM. Harvests were done after 2.5 
/ 4 / 16 / 19 hours at 25 °C. Cells were resuspended in 200 µl Lysis buffer 2. After the 
addition of 50 mg glass beads (Avestin), the suspension was homogenized in a tissue 
lyzer (30 Hz, 5 min) and centrifuged for 30 min at 14000 rpm. 10 µl of the supernatant 
were used for protein chip analysis (HT Protein Express Assay Kit, Caliper). Lysis and 
chip analysis were also performed for the uninduced sample. For test purification, 30 
µl MagneHis particles equilibrated in 2x200 µl binding buffer (MagneHis) were added. 
The suspension was incubated at on a shaker for 60 minutes (4°C, 1000 rpm) and then 
washed twice with 200 µl binding buffer (MagneHis). The bound protein was eluted by 
50 µl elution buffer (MagneHis) on a shaker at for 30 min (4°C, 1000 rpm). The eluate 
was analyzed by coupled liquid chromatography / mass spectrometry (LC/MS). 
The conditions of this protocol were varied in order to test the expression of other 
constructs than the FH2 construct:  
- Expression temperature: 16 °C (personal recommendation by D. Kovar) or 
25 °C  
- Time between induction and harvest: 2.5, 4, 16 or 20 hours 
- strains used for expression: E.coli Bl21-CodonPlus®(DE3)-RP or E.coli Bl21-
CodonPlus®-RP 
- YT medium or Terrific broth medium (personal recommendation by D. Kovar) 
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Large scale expression and purification of the FH2 construct (Core Facility of the 
Max Planck Institute for Biochemistry) 
 
Large scale expression was performed in a Labfors 3 (Infors HT) fermenter with Formin 
expression medium 2. During fermentation, 5 ml 0.01 ml/l Synperonic® (antifoaming 
agent) was added to the solution. The pH was held at 7 with KOH 20% and H3PO4 20%. 
The culture was grown for 5.5 hours at 37°C until OD600=9.56. It then was induced with 
0.5 mM IPTG at 25 °C for 16 hours (absolute final OD600 =57.8). After harvesting by 
centrifugation (8000 rpm, 10 min, 4 °C), a part of the biomass and uninduced sample 
was prepared for analysis by a protein chip assay. Another part of the biomass was 
purified. 
10 mg biomass was lysed in 60 ml Lysis Buffer (Avestin beads lysis method) and 
centrifuged for 30 minutes (20500 rpm, 4°C). 
Nickel Sepharose High Permormance beads (GE Healthcare) were added to the 
supernatant; the mixture was rotated on a wheel for 2 hours (4 °C, 200 rpm / min). It 
was washed twice with Formin washing buffer and eluted fractionwise with Formin 
eluation buffer (each fraction 1 – 1.5 ml). Intermittent centrifugation steps were 
always performed for 5 minutes (4°C, 1000 rpm). Small portions of the eluate 
fractions were used for Bradford assays and chip analyses (see above). Washing 
fractions and lysate were also analysed. 
Elution fractions were desalted by a Hi Prep 26/10 Desalting column (GE Healthcare) 
and Sephadex G-25 beads (Formin gel filtration & storage buffer). Protein containing 
fractions and protein concentration were identified by UV absorption. The protein was 
analyzed by coupled liquid chromatography / mass spectrometry (LC/MS). Other 
analytical gel filtrations were performed to check for multimerization of the protein. 
Cross-linked agarose and dextran beads, the column Superdex 75 10/300 GL (GE 
Healthcare) and the column Superdex 200 10/300 GL (GE Healthcare) were used. 
Directly after production, formin aliquots were flash frozen with liquid nitrogen and 
stored in the -80°C fridge. Handling of the FH2 protein is discussed in chapter 4.5. 
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4.4 Actin purification, labelling, storage and handling 
Actin was purified from chicken breast acetone powder according to a modified 
procedure described by Spudich and Watt [119]. All procedures, including procedures 
with labelled actin, were done in the cold room and/or on ice. All given 
concentrations are end concentrations. 
Chicken breast acetone powder was put for 30 minutes into a flask with G buffer 
(20 ml per gram acetone powder). The liquid was then filtered through a bandage, 
and the wet powder in the bandage was squeezed. This extraction procedure was 
repeated. After centrifugation for 30 minutes (Sorvall Evolution RC centrifuge, 
SLA1500 rotor, 30000 g, 4°C) the supernatant was polymerized at 4 °C by addition of 
50 mM KCl and 2 mM MgCl2. After at least two hours, tropomyosin and troponin were 
extracted with 800 mM KCl. The flask was put for 1.5 hours on a shaker (≈ 0.5 Hz). The 
mixture was centrifuged for 3 hours (ThermoScientific WX Ultra90 centrifuge, S52 ST 
rotor, 156000 g, 4°C). 
The pellet was resuspended with G-buffer and dialyzed against G-buffer for 3 days, 
changing it every 24 hours. The depolymerized actin was purified by gel filtration 
(column material: Sephacryl S-300 High Resolution, GE healthcare). The eluate 
fractions (Fraction Collector Frac-950, Amersham Biosciences) were checked for 
protein presence by absorption measurements (quartz cuvette, λ = 290 nm). A typical 
eluate profile and the fractions typically pooled are shown in Figure 29. The actin 
concentration of the pooled fractions was documented. 
Several methods for the storage of small actin aliquots (200-300 µl) were tested. 
Freeze drying (Christ Alpha 2-4 LSC Freeze dryer) was the method proven to be best 
for getting actin with a relatively reproducible function in pyrene assays. 
G buffer was added to freeze dried actin before starting pyrene assays. Actin was then 
dialysed against G buffer for 3 hours. Absorption (λ = 280 nm, λ = 290 nm) was 
documented for actin concentration determination. The actin sample was usually 
considered good only for about 24 hours. A pyrene assay several hours after the 
absorption measurement required another absorption measurement. 
 
Pyrene Actin (reported labelling efficiency: 85%) was available from the lab collection 
in frozen aliquots. After defrosting on ice, it was centrifuged for 40 minutes 
(Themoscientific Sorvall Discovery M120 SE centrifuge, S100-AT3 rotor, 60000 rpm, 
4°C). Absorptions (280, 290, 344 nm) were documented right before the 
measurements. A pyrene actin lot was used for not more than 5 days. 
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Figure 29: Actin purification, typical gel filtration eluate profile. The pooled fractions – later 
fractions in the big peak - are marked with red crosses. No baseline correction.  
 
 
4.5 Pyrene assays 
Pyrene Assays with formin and actin were found to be very sensitive to reaction 
conditions. The following very detailed protocol helps to make the data as 
reproducible as possible. 
Assays were performed with a Cary Eclipse Fluorospectrometer and a 4-cell sample 
holder. The cell holder temperature was set to 20 °C. Detector voltage was set to 
700 mV. Excitation wavelength was 365 nm, emission wavelength was 407 nm. In the 
first hour of the measurement, the maximum possible number of data points was 
collected. Afterwards, data points were collected every 10 seconds. Maximum 
measurement time was 12 hours. 
KMEI buffers with variable KCl concentrations between 100 mM and 900 mM (end 
concentrations: 10 x diluted) were used in the experiments. 
Before the start of the experiment, actin absorption (λ = 290 nm) and pyrene actin 
absorptions (λ = 290 nm, λ = 344 nm) were measured. With the absorption data, actin 
concentrations of both protein solutions and pyrene actin concentrations were 
calculated (εPyAc,344 = 22000 M
-1cm-1, εPyAc,344 = 22000 M
-1cm-1). A344(PyAc) * 0.127 was 
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subtracted from A290 when calculating the actin concentration in pyrene actin 
solution.  
70 µl of protein mix of actin and pyrene actin in G buffer were prepared in order to 
reach certain actin and pyrene concentrations. 
FH2 protein concentration was not measured prior to the assay; it was empirically 
found that it is most effective to refer to the FH2 concentration (54.34 µM) measured 
after protein production (shortly before it was frozen).  
A starter mix of 10 µl FH2 in G buffer and 10 µl KMEI buffer (with 10 mM < c(KCl) < 90 
mM). In few experiments, the starter mix contained also 15 mM to 150 µM NaCl. 
70 µl of the pyrene assay protein starter mix were mixed with 10 µl ME buffer for Ca2+ 
exchange and filled into a quartz cuvette. Exactly five minutes later, the fluorescence 
measurement was started. After 60 seconds, 20 µl of the starter mix were added. 
Usually four measurements were done simultaneously. 
For the analysis of pyrene assay data, normalization is necessary. Normalization 
reference should be the plateau of the measured intensity curve. Some of the 
experiments were performed at conditions that did not permit a visual determination 
of the plateau because it was not reached at the end of the measurement (f.e. due to 
extreme salt concentrations). Therefore it was necessary to fit the experiment to a 
model. 
Due to the exponential character of elongation kinetics (see chapter 1.1), it can be 
approximated by a multi-step reaction with a stationary state.  
[2]     
( ) ( ) ( )( )
( )
max 1 exp
polymerization rate;  = time
 = concentration of actin monomers which are part of f-actin
t p
p
c Actin c Actin k t
k t
c Actin
= ⋅ − − ⋅
=  
The concentration of actin monomers in f-actin (not g-actin) is proportional to the 
intensity measured in pyrene assays, the formula can be adapted accordingly. 
Moreover, the above formula still does not take into account that this reaction is 
delayed due to the nucleation processes. This delay can be implemented in the 
formula as a lag phase: 
[3]     
( )( )( )max
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1 exp
intensity; =maximum intensity
polymerization constant;  = time;
 = lag time
t p lag
p
lag
I I k t t
I I
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t
= − − ⋅ −
=
=
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The curve has only an exponential shape exponential when the elongation process 
dominates; therefore, the fit is performed only for data after the inflection point, 
which is determined by calculating the derivative of the smoothed data. Matlab (The 
MathWorks™, Matlab®, version 7.7.0.471, 2008) was used for data processing. Data 
processing steps are visualized in Figure 30. The general procedure will be commented 
in this chapter, more specific comments can be found in the code (see Appendix, 
chapter 5.1). 
Smoothing with the Matlab function spaps requires a smoothing parameter, which was 
chosen in order to fit the data close to the inflection point well and to yield a 
satisfyingly smooth derivative. This method normally yielded unequivocal results for 
tmax; however, the derivative turned out to be very sensitive on smoothing parameter 
settings. 
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Figure 30: Essential steps in pyrene assay data processing. Top: data smoothing and 
derivative of the smoothed curve. Determination of tmax.  Bottom: Fit to the data (only > tmax,  
secondary scale: after normalization). Determination of m at t1/2 (t1/2 = t at I1/2) Illustration of 
tlag, which is derived from the fit. Imax (2*I1/2) and kp (not shown) are also derived from the fit.   
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Once Imax is determined by the fit, the t1/2 can be determined (at t1/2). The slope m at 
t1/2 is a common empirical parameter, which represents the polymerization speed [48]. 
This slope turns out to be very sensitive to the derivative, which is based on the 
smoothed data. It turned out that m at t1/2 is often very different than m at tmax 
(especially at extreme salt conditions which often occur in this work). The first order 
reaction constant kp (from the fit) is yielded from the fit and also represents 
polymerization speed, based on the assumption that the polymerization kinetics after 
tmax is exponential. A more exact description of elongation kinetics would be possible 
with the two constants k+ and k-. Association velocity is given by c(free Actin) * k+ and 
is therefore concentration dependent. Dissociation velocity is directly given by k- and 
not concentration dependent. The equation above does not take this difference into 
account, therefore sufficiently high actin concentrations (3 µM) will be chosen so that 
the fit will match well especially in regions where k+
 * c(Actin) >> k-. 
The parameter turned out to be relatively insensitive to the smoothing parameter. 
Both kp and m will be given in the results part. 
tlag is classically derived from t1/2 and m at m with the formula 
[4] ( ) 1/ 20.5lag m tt classical
m
− ⋅
= −  
Due to the aspects mentioned above, this parameter often did yield hardly 
reproducible or sometimes even negative results (m at t1/2 smaller than m at tmax) for 
tlag. Therefore the tlag values yielded from the fit curve were used. In this work tlag is 
defined as the time at which the exponential curve of the elongation process crosses 
the time axis (formula 4).  
4.6 Fluorescence microscopy 
An actin polymerization assay with or without formin was run. When a steady state 
was reached (no formin: after 120 minutes), 5 µl Alexa488-phalloidin were added to 
the polymerization assay product (100 µl). 5 µl polylysine solution were put on a 
coverslip. After 10 minutes the solution was diluted 100 fold with the same buffer 
which was used for actin polymerization. The solution was spread on the polylysine 
covered coverslip. Images of 40-50 different fields of view were taken with the 
epifluorescence microscope.  
 
Actin filament lengths were measured manually with ImageJ (Wayne Rasband, 
National Institutes of Health, USA, version 1.43u). In order to avoid human bias, the 
experimental conditions were not revealed during the measurements. The following 
filaments were excluded from counting: 
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- short filaments < 15 px (~ 1.3 nm). Some images had a low image quality. In these 
cases, the short filaments were hardly distinguishable from background or 
unidentified aggregates. It is common to exclude very short filaments from length 
distribution determinations [120]. 
- branched filaments 
- circular filaments 
- filaments with a pronounced serpentine shape 
- any filament that was not unambiguously a single filament 
- filaments leaving the image (manual correction of the viewing field was not done to 
avoid human bias) 
These conditions left only little space for interpretation and therefore minimized 
human bias. However, the number of long filaments will be underestimated because 
most exclusions apply more often to very long filaments. Therefore a comparison of 
filament length distributions can only be of qualitative nature. The number of count 
filaments was 100-122 for experiments without and 218-299 for experiments with FH2 
mediated actin polymerization. The number of viewing fields was 5-8 for experiments 
without FH2 and 7-20 for experiments with FH2 mediated actin polymerization. 
 
In the beginning of actin polymerization experiments, the filament size distribution is 
not exponential. Close to steady state, fragmentation and annealing dominate the size 
distribution [121].  
Without fragmentation, a wide and irregular peak at higher filament lengths would be 
expected [121]. Fragmentation leads to an exponential size distribution at steady 
state [121]. An effect of formins on fragmentation is not expected due to the position 
of the formin at the barbed (+) end. Therefore, an exponential size distribution was 
assumed at steady state. After several hours at steady state, the exponential size 
distribution constant was shown to change; it is shifted to lower filament sizes with 
time [120]. This size shift depends on c(KCl) and is more pronounced at high salt 
concentrations [120]. Therefore, size distributions were measured very soon after 
reaching steady state to avoid a fragmentation-mediated shift of the exponential 
distributions to lower sizes. However, the size distribution of actin filaments < 3 µm 
cannot undoubtfully be described by a a single exponential [120], though an 
exponential fit is expected to be good enough for empirical size distribution 
description.  
 
The size distribution was fit to the equation 
[5]      ( )expy a bx= ⋅  
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y is a probability density, x is the filament length in pixels (1 px ≈ 85 nm), b is 
negative. 
 
For this operation, the Matlab (The MathWorks™, Matlab®, version 7.7.0.471, 2008) 
Curve Fitting Toolbox™ (least-squares method) was used. For visual confirmation of 
monomodal distribution, histograms with a bin size of 10 px or 15 px were also 
generated. 
 
Annealing is a common process occurring in F-actin solutions. It has a big impact on 
actin filament size distribution [122]. Formin proteins can partially protect actin from 
annealing [117]. Therefore, it is difficult to compare length distributions of formin-
mediated actin polymerizations with those of non-formin-mediated polymerizations. 
In order to protect samples from annealing, particular attention was paid to treat 
them equally. Especially mechanical fragmentation by repeated uptake with a pipette 
was avoided as much as possible. After 1:100 dilution annealing events are expected 
to be rare. 
4.7 Calculation of electrostatic energies and calculation of solvent 
accessible surface areas (SASAs) 
All electrostatic energy calculations are based on PDB protein structure 1Y64, which 
contains the interaction of an actin molecule with a Bni1p FH2 domain [36]. Two 
isolated structures, namely actin only and FH2 only, were generated from this 
dataset. The actin structure contains a modified histidine residue and a tetramethyl 
rhodamine dye; however, interactions between actin and the FH2 domain take place 
in areas of the protein that are not close to these modifications. Two other PDB 
protein structures, one with actin alone and one with FH2 alone, were derived from 
this file with PyMol™ (The PyMOL Molecular Graphics System, version 1.3, Schrödinger, 
LLC). 
For electrostatic energy calculations, the structure has to be prepared first, based on 
a certain force field. Several force field algorithms are available [123]. The structure 
was calculated with the PDB2PQR server application using different force fields [124, 
125]. PropKa [126] was used for assigning protonation at pH = 7.1 (same pH during 
actin polymerization experiments). Electrostatic energies and the electrostatic 
surface energies were calculated with APBS 1.3 [127]. The input file for this program 
was generated with PyMOL ABPS Tools 2.1 (MG Lerner and HA Carlson. APBS plugin for 
PyMOL, 2006, University of Michigan, Ann Arbor) and modified manually. All 
electrostatic energy calculations were performed for two different KCl concentration 
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levels (10 and 90 mM, and c(MgCl2) = 1.05 mM). In order to derive binding energies, 
energies were calculated for the FH2/actin complex, for FH2 alone and for Actin 
alone. 
The electrostatic energies were first calculated for one small area of protein 
interaction. For these calculations, an automatically-configured focussing multigrid 
method, the non-linear Poisson-Boltzmann equation and multiple Debye-Hückel 
spheres were chosen. The calculations were performed for force fields calculated by 
two different standard force fields, CHARMM27 and AMBER94. The choice of the 
protein dielectric εr is not trivial [128]. Assuming an approximately apolar 
environment inside the protein, it could be set to 1 [123, 128]. The standard choice 
for the dielectric by ABPS and PDB2PQR is 2. Other sources suggest an εr between 2 
and 4 [129, 130].  According to the APBS documentation higher εr (up to 20) take into 
account intramolecular motion to a greater extent. The electrostatic calculations 
were therefore performed for several εr (1, 2, 4, 8, 12). The solvent dielectric (water) 
was set to the standard value of 78, while the solvent radius was set to 1.4 for water 
and to 0 for vacuum (vacuum calculations are needed for electrostatic solvation 
energy calculations). 
Surface potential was visualized with PyMOL ABPS Tools 2.1 (MG Lerner and HA 
Carlson. APBS plugin for PyMOL, 2006, University of Michigan, Ann Arbor). The 
electrostatic energies for these visualizations were calculated for the whole proteins 
and for the protein complex using the standard protein dielectric εr = 2. One 
visualization type was the colouring of the solvent accessible potential. The other 
visualization type was the depiction of isosurfaces at ±1 kT/e. 
For the evaluation of electrostatic energies, it is important to note that their absolute 
values are inaccurate and not useful. They always have to be put in relation to other 
values.  
The main question to be addressed is: Is the binding of actin to FH2 energetically 
more favourable at low salt concentrations than at high concentrations? 
 
The binding free energy of Actin and FH2 is 
[6] ( )( , 2) ( 2) ( ) ( 2)B elec elec water elec elec waterG Actin FH G ActFH G Actin G FH∆ = − +  
If this energy is negative, a binding of actin and FH2 is energetically favourable. In this 
work, electrostatic energy changes upon salt transfer are defined as 
[7] 
, ,salt elec elec lowsalt elec highsaltG G G∆ = −  
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In order to evaluate whether ∆BGelec(Act,FH2) is more favourable at low salt 
concentrations than at high salt concentrations, the difference between 
∆BGelec(Act,FH2) at low and at high salt concentrations must be calculated:  
[8] 
( )
( , 2) ( 2)
( ) ( 2)
B salt elec salt elec water
salt elec water salt elec water
G Actin FH G ActFH
G Actin G FH
∆ ∆ = ∆
− ∆ + ∆     
Note: ∆Salt∆BGelec(Act, FH2) = ∆B∆SaltGelec(Act, FH2) 
 
A negative value of ∆B∆SaltGelec(Actin, FH2) would mean (considering equations [8] and 
[9]) that a salt concentration change from high to low salt would favour the 
interaction between Actin and FH2 (= lower their electrostatic binding free energy). 
 
Electrostatic solvation energies can be generally calculated with 
[9] 
, ,S elec elec water elec vacuumG G G∆ = −  
  
The electrostatic binding free energy of Actin and FH2 can be split into a solvation and 
a Coulomb part: 
[10]  ( , 2) ( , 2) ( , 2)B B S B CG Actin FH G Actin FH G Actin FH∆ = ∆ ∆ + ∆ ∆  
 
The solvation part of the electrostatic binding free energy upon transfer from high to 
low salt is – in analogy to [8]:  
[11]  
( )elec elec( , 2) ( 2) ( ) ( 2)B salt S elec salt S salt S elec salt SG Actin FH G ActFH G Actin G FH∆ ∆ ∆ = ∆ ∆ − ∆ ∆ + ∆ ∆
 
In order to estimate the Coulomb part of the electrostatic binding free energy upon 
the transfer from high to low salt, the salt concentration has to be implemented into 
the reshuffled equation [11], and with equation [12] the following equation is yielded: 
 
[12] ( , 2) ( , 2) ( , 2)B salt C elec B salt elec B salt S elecG Actin FH G Actin FH G Actin FH∆ ∆ ∆ = ∆ ∆ − ∆ ∆ ∆  
 
These calculations of ∆B∆SaltGelec(Actin, FH2) and ∆B∆Salt∆CGelec(Actin, FH2) have only 
been performed for a single specific interaction area between Actin and FH2.  
 
Solvent accessible surface areas (SASA) were computed for the Actin-FH2 complex of 
the 1Y64 crystal structure by the ANCHOR web server [108]. 
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5 Appendix 
5.1 Matlab code for processing pyrene assay data 
see chapter 4.5 for further information 
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5.5 Abstract 
Formin proteins are actin nucleators and elongators which can be found in most 
eukaryotic cells. In this work, structure-function relationships between yeast formin 
Bni1p and actin polymerization were studied. 
In the first part of this work, it was attempted to clone and express formin constructs 
derived from yeast Bni1p (Saccharomyces cerevisiae), including the key FH2 domain 
and a modified FH1 domain. Biomathematical models involving both diffusion and 
concentration-limited actin recruitment kinetics could be tested with such proteins. 
Cloning was mostly successful, but only the FH2 domain alone was expressed. 
In the second part of this work, a salt effect on FH2 mediated actin nucleation was 
discovered by means of pyrene assays and epifluorescence microscopy. Potassium 
chloride (KCl) is a downregulator of FH2 nucleation activity: a higher KCl 
concentration leads to a significantly lower actin polymerization speed (kp, m), to a 
bigger lag time (tlag) and to a bigger t1/2, with the respective actin filament length 
distributions. The salt effect was shown to be significant in a KCl concentration range 
from 10 mM to 90 mM at two different FH2 concentration, but not in absence of FH2. 
The critical KCl concentration is lowered in the presence of FH2. Some initial 
experiments with sodium chloride point to a non-specific nature of this salt. This is in 
agreement with the electrostatic nature of the salt effect, which was studied further 
by computational means: A decrease of the KCl concentration leads to lower binding 
free energies of the protein-protein interactions in the crystallographically 
characterized actin-FH2 complex 1Y64. This is especially the case for the electrostatic 
Coulomb interaction of a specific area ("lasso" site). ANCHOR calculation results of 
solvent accessible surface areas (SASAs) corroborate the importance of this site.  
The experimentally found downregulation of FH2 mediated actin nucleation by KCl can 
therefore be explained by reduced actin recruitment by the FH2 dimer: KCl diminishes 
the surface charge of FH2 and actin and thus weakens electrostatic Coulomb 
interactions.  
In future, this newly discovered salt effect should be considered in experiments on 
formins, for example when performing in vitro screens for FH2 inhibitors. The 
relevance of this new salt effect in vivo remains to be demonstrated. 
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5.6 Zusammenfassung in deutscher Sprache 
Forminproteine sind Aktinnukleatoren und -elongatoren, die in fast allen 
eukaryotischen Zellen vorkommen. Es wurden in dieser Arbeit Struktur-Funktions-
beziehungen zwischen dem Hefeformin Bni1p und der Aktinpolymerisation untersucht. 
  Im ersten Teil der Arbeit wurde versucht, verschiedene Forminkonstrukte 
des Hefeformins bni1p (Saccharomyces cerevisiae) mit der Schlüsseldomäne FH2 und 
gegebenenfalls modifizierter FH1-Domänen zu exprimieren, um damit biomathe-
matische Modelle testen zu können, die sowohl eine diffusions- als auch eine 
konzentrationslimitierte Kinetik der Aktinrekrutierung annehmen. Die meisten 
Klonierungen gelangen, exprimiert werden konnte jedoch nur die FH2-Domäne allein.  
Pyrene-Assays und epifluoreszenzmikroskopische Aufnahmen konnten im zweiten Teil 
der Arbeit einen bisher nicht bekannten Salzeffekt auf die FH2-vermittelte 
Aktinnukleation nachweisen. Der Salzeffekt wurde für Kaliumchlorid (KCl) im 
Konzentrationsbereich 10 mM < c(KCl) < 90 mM untersucht und war signifikant für zwei 
Versuchsserien mit unterschiedlichen FH2-Konzentrationen, jedoch nicht in 
Abwesenheit von FH2. KCl reguliert im genannten Konzentrationsbereich die 
Aktinnukleationsaktivität von FH2 herunter: Eine höhere KCl-Konzentration führt zu 
einer signifikant niedrigeren Polymerisationsgeschwindigkeit (kp, m), zu einer 
größeren lag time (tlag) und zu einer größeren t1/2, mit einer dazu passenden 
Längenverteilung der Aktinfilamente. Die kritische KCl-Konzentration sinkt in 
Anwesenheit von KCl. Erste Experimente mit Natriumchlorid deuten an, dass der 
Effekt unspezifisch ist. Das passt zu der elektrostatischen Natur dieses Salzeffektes, 
die auch bioinformatisch untersucht wurde: Für eine niedrigere KCl-Konzentration 
wurden niedrigere freie Bindungsenergien für die Protein-Protein-Interaktion eines 
kristallographisch beschriebenen Aktin-FH2-Komplexes (1Y64) berechnet. Das gilt 
insbesondere für die elektrostatischen Coulomb-Wechselwirkungen eines bestimmten 
Bereiches (Lasso). ANCHOR-Berechnungen der der exponierten Proteinoberflächen 
(SASAs) weisen ebenfalls auf die Bedeutung dieses Bereiches hin.  
Die Herunterregulierung der FH2-vermittelten Aktinnukleation durch Kaliumchlorid 
kann daher mit einer reduzierten Aktinrekrutierung durch das FH2-Dimer erklärt 
werden: KCl vermindert die Oberflächenladung von FH2 und Aktin und schwächt so 
elektrostatische Coulomb-Wechselwirkungen.  
In der Zukunft sollte dieser neu gefundene Salzeffekt bei in vitro - Experimenten mit 
Forminen berücksichtigt werden, zum Beispiel beim Screening nach FH2-Inhibitoren. 
Es ist künftig ferner von Interesse, welche Folgen dieser neu gefundene Salzeffekt auf 
die FH2-vermittelte Aktinnukleation in vivo hat. 
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